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Abstract 
Cancer screening can prevent mortality and morbidity from cancer, but it also causes harms. 
Recently, precision (i.e. risk-based, personalized) screening approaches have emerged as a way to 
better balance these benefits and harms. The purpose of this dissertation was to identify 
opportunities for precision screening among two U.S. populations at high risk for cancer: people 
living with HIV and people with a history of heavy smoking. 
 
The first aim (Chapter 2) analyzed data from the Women’s Interagency HIV Study to compare 
cervical precancer risks between women living with HIV (WLHIV) and general population women. 
We used a risk benchmarking framework to draw conclusions regarding appropriate cervical cancer 
screening and management strategies for WLHIV. We show that current guidelines are largely 
appropriate, but that in some instances, considering CD4 cell count (immunosuppression status) 
could inform risk-tailored strategies. 
 
The second aim (Chapter 3) analyzed data from the Multicenter AIDS Cohort Study (MACS) to 
describe patterns of repeated anal cytology testing among HIV-positive and HIV-negative men who 
have sex with men (MSM). We show that approximately one-third of HIV-positive MSM have 
consistently negative anal cytology over 3 years, which may identify men for whom high-resolution 
anoscopy is unlikely to be beneficial. Following abnormal anal cytology, the next cytology is 
commonly negative in HIV-negative or immunocompetent HIV-positive MSM, while persistent 
cytological abnormality is more likely among immunosuppressed HIV-positive MSM. 
 
Finally, the third aim (Chapter 4) develops a risk model to describe how individual lung cancer risk 
evolved based on screening CT findings during the National Lung Screening Trial. We show that 
those with a negative CT screen and no emphysema or consolidation maintained reduced lung cancer 
risk at the next annual screen and thus might be candidates for longer screening intervals. In contrast, 
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most false-positives experienced substantially increased lung cancer detection at the next screen, 
which could be stratified by accounting for specific features of lung nodules. 
 
In sum, this dissertation describes three settings in which precision cancer screening could achieve a 
better balance of benefits and harms for two high-risk populations. Success in implementing these 
approaches will require interdisciplinary efforts that engage clinicians, patients, and researchers.  
     iv 
 
Dedication 
This dissertation is dedicated to my great-uncle Dr. Lewis C. Robbins. During a long and 
remarkable career in preventive medicine, “Uncle Louie” served as the first chief of cancer control 
programs in the U.S. Public Health Service (1957-1965). He helped write the surgeon general’s first 
warning on tobacco, which was published in JAMA under Leroy R. Burney’s signature in 1959. 
Louie pioneered the concept of “prospective medicine,” which statistically assessed patients’ 
behavioral health risks and offered tailored advice to improve health and increase life expectancy. 
These individualized “health hazard appraisals” might be considered one of the early examples of 
precision medicine. 
Uncle Louie earned his MPH at Johns Hopkins and is listed as one of the “Heroes of Public 
Health” on the Johns Hopkins Bloomberg School of Public Health webpage. Much of his writings 
and records are now kept in the Lewis C. Robbins collection at the JHU Alan Mason Chesney 
Medical Archives. I did not have the chance to meet him, as he died shortly after I was born, but I 
continue to be inspired by his work and ideas. 
  
     v 
Dissertation Advisors and Readers 
Gypsyamber D’Souza, PhD, Thesis Advisor and Reader 
Associate Professor, Epidemiology, Johns Hopkins School of Public Health 
 
Hormuzd A. Katki, PhD, Co-Advisor 
Senior Investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute 
 
Scott Zeger, PhD, Co-Advisor and Reader 
Professor, Biostatistics, Johns Hopkins School of Public Health 
 
Kala Visvanathan, MD MHS FRACP, Co-Advisor and Reader 
Professor, Epidemiology, Johns Hopkins School of Public Health 
 
Anne F. Rositch, PhD, Co-Advisor 
Assistant Professor, Epidemiology, Johns Hopkins School of Public Health 
 
John Groopman, PhD, Reader 
Professor, Environmental Health and Engineering, Johns Hopkins School of Public Health 
 
  
     vi 
Acknowledgments 
 This work would not have been possible without the financial support I received from the 
following sources: the Cancer Epidemiology, Prevention, and Control Training Grant (NCI T32 
CA009314), an individual F31 Ruth L. Kirschstein National Research Service Award (NCI F31 
CA210660), the Jean Coombs Award (Department of Epidemiology, JHSPH), the Carol Eliasberg 
Martin Scholarship (JHSPH), the Alison Snow Jones Prize (Department of Health Policy and 
Management, JHSPH), the David and Elinor Bodian Scholarship (JHSPH), and the Kocherlakota 
Award (Department of Biostatistics, JHSPH). I am also grateful for the support I received for travel 
to scientific conferences from the following organizations: the Huntsman Cancer Institute, the 
American Association for Cancer Research, the International Papillomavirus Society, the American 
Thoracic Society, and the International Cancer Screening Network. 
 My dissertation work was supervised primarily (Aims 1 and 2) by Dr. Gypsyamber D’Souza, 
Associate Professor in Epidemiology at JHSPH, and secondarily by Dr. Hormuzd Katki (Aim 3), 
Senior Investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer 
Institute. Drs. Scott Zeger, Kala Visvanathan, and Anne Rositch provided additional guidance as part 
of my thesis advisory committee. I am incredibly grateful to these individuals for their mentorship, 
support, and advice on topics often ranging far outside the confines of my dissertation. I additionally 
thank Drs. Miranda Jones, Lisa Jacobson, Roger Peng, Craig Pollack, Megan Moran, Eric Seaberg, 
and John Groopman for serving on my departmental, preliminary, and final oral examination 
committees. Finally, I have benefitted immensely from the ongoing friendship and mentorship of 
Drs. Eric Engels, Meredith Shiels, Mahboobeh Safaeian, and Christine Berg, as my success in 
completing a PhD has been in no small part enabled by what I have learned from working with 
them. 
 Throughout my studies, I have been surrounded by an incredible group of fellow students, 
family, and friends. I am grateful in particular to my fellow Epidemiology and JHSPH doctoral 
students, who have collectively spent countless hours reviewing and providing feedback on my 
     vii 
writing, talking through analytical or conceptual challenges, helping me prepare for written and oral 
examinations, previewing my presentations, providing a sounding board when I encountered 
challenges, and simply ensuring that writing this dissertation was not a lonely endeavor. I am grateful 
to my mother, father, and sister, and to my mother-, father-, and brothers-in-law for their love and 
support. Finally, I thank my husband Dan, who was the core of my support system and brought joy 
and perspective to each of my days while I pursued my PhD. 
 
Publications and Co-authors 
Chapter 2 was published in AIDS in 2017 (31:1035-1044) by authors Hilary A. Robbins 
(Johns Hopkins Bloomberg School of Public Health, Baltimore, MD), Howard D. Strickler (Albert 
Einstein College of Medicine, Bronx, NY), L. Stewart Massad (Washington University School of 
Medicine, St. Louis, MO), Christopher B. Pierce (Johns Hopkins Bloomberg School of Public Health, 
Baltimore, MD), Teresa M. Darragh (University of California San Francisco, San Francisco, CA), 
Howard Minkoff (Maimonides Medical Center, Brooklyn, NY), Marla J. Keller (Albert Einstein 
College of Medicine, Bronx, NY), Margaret Fischl (University of Miami Miller School of Medicine, 
Miami, FL), Joel Palefsky (University of California San Francisco, San Francisco, CA), Lisa Flowers 
(Grady Memorial Hospital and Emory University School of Medicine, Atlanta, GA), Lisa Rahangdale 
(University of North Carolina School of Medicine, Chapel Hill, NC; University of Southern 
California, Los Angeles, CA), Joel Milam (University of Southern California, Los Angeles, CA), 
Sadeep Shrestha (University of Alabama at Birmingham School of Public Health, Birmingham, AL), 
Christine Colie (Georgetown University Medical Center, Washington DC), and Gypsyamber D’Souza 
(Johns Hopkins Bloomberg School of Public Health, Baltimore, MD). The paper was accompanied 
by a commentary written by Silvia Franceschi and Gary M. Clifford (International Agency for 
Research on Cancer, Lyon, France). 
Chapter 3 will soon be published in Papillomavirus Research by authors Hilary A. Robbins 
(Johns Hopkins Bloomberg School of Public Health, Baltimore, MD), Dorothy Wiley (University of 
     viii 
California Los Angeles School of Nursing, Los Angeles, CA), Ken Ho (University of Pittsburgh 
School of Medicine, Pittsburgh, PA), Michael Plankey (Division of Infectious Diseases, Georgetown 
University Medical Center, Washington, DC), Susheel Reddy (Department of Infectious Disease, 
Northwestern University, Chicago, IL), Nancy Joste (University of New Mexico Health Sciences 
Center, Albuquerque, NM and Tricore Reference Laboratories, Albuquerque, NM), Teresa M. 
Darragh (Department of Pathology, University of California San Francisco, San Francisco, CA, 
USA), Elizabeth C. Breen (Cousins Center for Psychoneuroimmunology, David Geffen School of 
Medicine, University of California Los Angeles, Los Angeles, CA), Stephen Young (University of 
New Mexico Health Sciences Center, Albuquerque, NM and Tricore Reference Laboratories, 
Albuquerque, NM), and Gypsyamber D’Souza (Johns Hopkins Bloomberg School of Public Health, 
Baltimore, MD). 
Chapter 4 will be submitted for publication by authors Hilary A. Robbins (Department of 
Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland and 
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland), 
Christine D. Berg (Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
Rockville, Maryland), Li C. Cheung (Division of Cancer Epidemiology and Genetics, National Cancer 
Institute, Rockville, Maryland), Anil K. Chaturvedi (Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Rockville, Maryland), and Hormuzd A. Katki (Division of Cancer 
Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland). 
 
  
     ix 
Table of Contents 
 
List of Tables ....................................................................................................................................................... xi 
List of Figures .................................................................................................................................................... xiii 
List of Abbreviations ........................................................................................................................................ xvi 
Chapter 1: Introduction ...................................................................................................................................... 1 
1.1 Cancer in High-Risk Populations: HIV and Smoking ........................................................................ 1 
1.2 Cancer Screening as a Tool to Reduce Cancer Burden ...................................................................... 3 
1.3 Precision Medicine and Cancer Screening ............................................................................................ 4 
1.4 HPV as a Cause of Cancer in People Living With HIV ..................................................................... 4 
1.5 Cervical Cancer Screening in Women Living with HIV ..................................................................... 6 
1.6 Anal Cancer Screening in Men Who Have Sex With Men ................................................................ 7 
1.7 Lung Cancer Screening in Heavy Smokers ........................................................................................... 8 
1.8 Tables and Figures .................................................................................................................................. 10 
Chapter 2: Cervical Cancer Screening Intervals and Management for Women Living with HIV: A 
Risk Benchmarking Approach ......................................................................................................................... 12 
2.1 Abstract .................................................................................................................................................... 12 
2.2 Introduction ............................................................................................................................................. 13 
2.3 Methods .................................................................................................................................................... 14 
2.4 Results ....................................................................................................................................................... 17 
2.5 Discussion ................................................................................................................................................ 20 
2.6 Supplementary Methods ........................................................................................................................ 23 
2.7 Acknowledgments .................................................................................................................................. 25 
2.8 Tables and Figures .................................................................................................................................. 27 
Chapter 3: Patterns of Repeated Anal Cytology Testing among HIV-positive and HIV-negative Men 
who have Sex with Men .................................................................................................................................... 40 
     x 
3.1 Abstract .................................................................................................................................................... 40 
3.2 Introduction ............................................................................................................................................. 41 
3.3 Methods .................................................................................................................................................... 42 
3.4 Results ....................................................................................................................................................... 44 
3.5 Discussion ................................................................................................................................................ 47 
3.6 Acknowledgments .................................................................................................................................. 50 
3.7 Tables and Figures .................................................................................................................................. 52 
Chapter 4: Updating Individual Lung Cancer Risk during CT Screening to Identify those who Might 
Lengthen Screening Intervals ........................................................................................................................... 58 
4.1 Abstract .................................................................................................................................................... 58 
4.2 Introduction ............................................................................................................................................. 59 
4.3 Methods .................................................................................................................................................... 60 
4.4 Results ....................................................................................................................................................... 62 
4.5 Discussion ................................................................................................................................................ 65 
4.6 Supplementary Methods ........................................................................................................................ 67 
4.7 Supplementary Results ........................................................................................................................... 71 
4.8 Tables and Figures .................................................................................................................................. 75 
Chapter 5: Conclusions ..................................................................................................................................... 87 
5.1 Summary of Results ................................................................................................................................ 87 
5.2 Opportunities for Future Research ...................................................................................................... 88 
Chapter 6: Bibliography .................................................................................................................................... 91 
Chapter 7: Curriculum Vitae .......................................................................................................................... 105 
  
     xi 
List of Tables 
 
Table 1.1: Descriptive epidemiology of cervical and anal cancers among people living with HIV in 
the United States ....................................................................................................................................... 10 
Table 2.1 General population studies analyzed to generate risk benchmarks of cervical intraepithelial 
neoplasia (CIN) for comparison to risks in women living with HIV. ............................................. 27 
Table 2.2 Descriptive characteristics of 2,423 women living with HIV in the Women’s Interagency 
HIV Study with negative or ASC-US cytology at their first visit in 2000 or later. ......................... 28 
Table 2.3 Summary of bHSIL+ (CIN2+) risks among women living with HIV and the cervical 
cancer screening strategies suggested by this risk benchmarking approach. ................................... 29 
Table 2.4 Summary of bHSIL+ (CIN3+) risks among women living with HIV and the cervical cancer 
screening strategies suggested by this risk benchmarking approach. ............................................... 30 
Table 3.1 Description of HIV-negative and HIV-positive men who have sex with men (MSM) in the 
MACS study with anal cytology testing ................................................................................................. 52 
Table 3.2 Frequencies of the next anal cytology result following 1 or 2 initial cytologies that were 
negative or abnormal among 976 MSM, by HIV and CD4 status at first cytology ....................... 53 
Table 3.3 Frequencies of the next anal cytology result following an initial negative or abnormal 
cytology result among 687 MSM, by HIV and CD4 status at first cytology, requiring an 18-30 
month interval between cytology results ............................................................................................... 54 
Table 3.4 Patterns of the first 3 consecutive anal cytology results among 328 HIV-positive MSM with 
at least 3 valid cytology results ................................................................................................................ 55 
Table 3.5 Prevalence of detailed anal cytology patterns among 328 HIV-positive men who have sex 
with men (MSM) with at least 3 valid cytologies ................................................................................. 56 
Table 3.6 Logistic regression model identifying risk factors for a pattern of first 3 consecutive 
abnormal anal cytologies (N=51) compared to first 3 consecutive negative cytologies (N=115) 
among HIV-positive MSM ...................................................................................................................... 57 
Table 4.1 List and description of all variables that describe specific features identified on CT ........... 75 
     xii 
Table 4.2 Selection of variables describing features identified on CT for inclusion in models of 
interval cancers, screen-detected cancer among screen-negatives, and screen-detected cancer 
among false-positives ............................................................................................................................... 76 
Table 4.3 Individuals and screens from the National Lung Screening Trial included in analysis of risk 
for interval and screen-detected lung cancer ........................................................................................ 77 
Table 4.4 Cross-validation for models of next-screen lung cancer detection and interval lung cancer 
risk that incorporate specific CT-image featuresa ................................................................................ 78 
Table 4.5 Calculation of next-screen lung cancer risk following a false-positive screen, based on 
Lung-RADS categories ............................................................................................................................ 79 
Table 4.6 Effect of features noted on a false-positive CT screen on 1-year risk of screen-detected 
lung cancer among participants in the National Lung Screening Trial ............................................ 80 
Table 4.7 Observed lung cancer incidence over 4 years following the final (T2) NLST screen, by 
quintile of model-predicted 1-year total lung cancer risk ................................................................... 81 
  
     xiii 
List of Figures 
 
Figure 1.1: Conceptual framework for applying risk-tailored methods in cervical and anal cancer 
screening ..................................................................................................................................................... 11 
Figure 2.1 Generation of bHSIL+ (CIN2+) risk benchmarks for a 3-year return (after negative 
cytology, panel A), a 6-12 month return (after ASC-US cytology, panel B), and immediate 
colposcopy (after LSIL cytology, panel C). Black lines depict summary risks generated by linear 
models with random intercepts, and black points indicate the 3-year risk benchmarks used for 
comparison to risks among women living with HIV. ......................................................................... 31 
Figure 2.2 Risk of cervical bHSIL+ (CIN2+) among 2,049 women living with HIV (WLHIV) 
following negative cytology, by CD4 cell count at the time of cytology and oncogenic HPV 
status, compared to general population risk benchmarks for recommending women be re-
screened in 3 years (3y return) or 6-12 months (6-12mo return). The Figure includes panels for: 
any oncogenic HPV result (positive, negative or unknown) (panel A), oncHPV-negative (panel 
B), or oncHPV-positive (panel C). Calculation of risks following a co-test result (panels B and 
C) was restricted to 1,194 women aged 30 years and older. .............................................................. 32 
Figure 2.3 Risk of cervical bHSIL+ (CIN2+) among 374 women living with HIV (WLHIV) following 
ASC-US cytology, by CD4 cell count at the time of cytology and oncogenic HPV co-test status, 
compared to general population risk benchmarks for recommending women be re-screened in 3 
years (3y return), 6-12 months (6-12mo return), or referred for immediate colposcopy. The 
Figure includes panels for: any oncogenic HPV result (positive, negative or unknown) (panel A), 
oncHPV-negative (panel B), or oncHPV-positive (panel C). Calculation of risks following a co-
test result (panels B and C) was restricted to 245 women aged 30 years and older. ...................... 33 
Figure 2.4 Risk of cervical bHSIL+ (CIN2+) among 374 women living with HIV (WLHIV) following 
ASC-US cytology, by CD4 cell count at the time of cytology, compared to general population 
risk benchmarks for recommending women be re-screened in 3 years (3y return), 6-12 months 
(6-12mo return), or referred for immediate colposcopy. ................................................................... 34 
     xiv 
Figure 2.5 Risk of cervical bHSIL+ (CIN2+) among women living with HIV (WLHIV) following 1, 
2, or 3 consecutive negative cytology results, by CD4 cell count at final cytology (≥500 panel A, 
<500 panel B), compared to a general population risk benchmark for recommending women be 
re-screened in 3 years (3y return). .......................................................................................................... 35 
Figure 2.6 Generation of bHSIL+ (CIN3+) risk benchmarks for a 3y return (after negative cytology, 
panel A), a 6-12mo return (after ASC-US cytology, panel B), and immediate colposcopy (after 
LSIL cytology, panel C). Black lines depict summary risks generated by linear models with 
random intercepts, and black points indicate the 3-year risk benchmarks used for comparison to 
risks among women living with HIV. .................................................................................................... 36 
Figure 2.7 Risk of cervical bHSIL+ (CIN3+) among 2,049 women living with HIV (WLHIV) 
following negative cytology, by CD4 cell count at the time of cytology and oncogenic HPV 
status, compared to general population risk benchmarks for recommending women be re-
screened in 3 years (3y return) or 6-12 months (6-12mo return). The Figure includes panels for: 
any oncogenic HPV result (positive, negative or unknown) (panel A), oncHPV-negative (panel 
B), or oncHPV-positive (panel C). Calculation of risks following a co-test result (panels B and 
C) was restricted to 1,194 women aged 30 years and older. .............................................................. 37 
Figure 2.8 Risk of cervical bHSIL+ (CIN3+) among 374 women living with HIV (WLHIV) following 
ASC-US cytology, by CD4 cell count at the time of cytology and oncogenic HPV co-test status, 
compared to general population risk benchmarks for recommending women be re-screened in 3 
years (3y return), 6-12 months (6-12mo return), or referred immediately for colposcopy. The 
Figure includes panels for: any oncogenic HPV result (positive, negative or unknown) (panel A), 
oncHPV-negative (panel B), or oncHPV-positive (panel C). Calculation of risks following a co-
test result (panels B and C) was restricted to 245 women aged 30 years and older. ...................... 38 
Figure 2.9 Risk of cervical bHSIL+ (CIN3+) among women living with HIV (WLHIV) following 1, 
2, or 3 consecutive negative cytology results, by CD4 cell count at final cytology (≥500 panel A, 
     xv 
<500 panel B), compared to general population risk benchmarks for recommending women be 
re-screened in 3 years (3y return). .......................................................................................................... 39 
Figure 4.1 Comparison of T2 screen-detected lung cancer risk between groups with the same screen 
result at T1, but a different result at T0 in the National Lung Screening Trial .............................. 82 
Figure 4.2 Overall effect of a negative or false-positive CT screening result on 1-year risk of an 
interval or screen-detected lung cancer among participants in the National Lung Screening Trial
 ..................................................................................................................................................................... 83 
Figure 4.3 Effect of features noted on a negative CT screen on 1-year risk of screen-detected lung 
cancer among participants in the National Lung Screening Trial ..................................................... 84 
Figure 4.4 Effect of features noted on a negative CT screen on 1-year risk of interval lung cancer 
among participants in the National Lung Screening Trial ................................................................. 85 
Figure 4.5 Effect of features noted on a false-positive CT screen on 1-year risk of screen-detected 
lung cancer among participants in the National Lung Screening Trial ............................................ 86 
  
     xvi 
List of Abbreviations 
 
AIDS: acquired immunodeficiency syndrome 
ASC-H: atypical squamous cell of undetermined significance, cannot exclude HSIL 
ASC-US: atypical squamous cell of undetermined significance 
bHSIL+: biopsy-confirmed high-grade squamous intraepithelial lesion or worse 
CDC: Centers for Disease Control and Prevention 
CIN: cervical intraepithelial neoplasia 
eART: effective antiretroviral therapy 
HIV: human immunodeficiency virus 
HPV: human papillomavirus 
HRA: high-resolution anoscopy 
HSIL: high-grade squamous intraepithelial lesion 
JHSPH: Johns Hopkins Bloomberg School of Public Health 
LCDRAT: Lung Cancer Death Risk Assessment Tool 
LCRAT: Lung Cancer Risk Assessment Tool 
(LD)CT: (low-dose) computed tomography 
LSIL: low-grade squamous intraepithelial lesion 
MACS: Multicenter AIDS Cohort Study 
MSM: men who have sex with men 
NCI: National Cancer Institute 
NLST: National Lung Screening Trial 
oncHPV: oncogenic human papillomavirus 
PLHIV: people living with HIV 
WIHS: Women’s Interagency HIV Study 
WLHIV: women living with HIV
     1 
Chapter 1: Introduction 
 
1.1  Cancer in High-Risk Populations: HIV and Smoking 
Cancer is “a group of diseases characterized by the uncontrolled growth and spread of 
abnormal cells.”1 While the cause of some cancers remains unknown, lifestyle-related risk factors 
cause many cancers in the United States; these factors include tobacco use (particularly cigarette 
smoking), excess body weight, low physical activity, excess alcohol consumption, and poor nutrition. 
Infectious agents are also an important cause of cancer, including helicobacter pylori (gastric cancer), 
hepatitis B virus (liver cancer), hepatitis C virus (liver cancer and non-Hodgkin lymphomas), human 
papillomavirus (HPV) (multiple oral and anogenital cancers), Epstein-Barr virus (Hodgkin’s 
lymphoma, Burkitt’s lymphoma, and nasopharyngeal cancer), human herpesvirus 8 (Kaposi’s 
sarcoma), and human T-cell lymphotropic virus (leukemia and lymphoma).2 
Taken together, infectious agents were estimated to cause 15.4% of the 2.2 million cancer cases 
worldwide in 2012.2 Among these, helicobacter pylori caused 35.4%, followed closely by HPV at 
29.5%. The proportion of cancers attributable to infections varies strongly by geographical region, 
ranging from a maximum of 31.3% in sub-Saharan Africa to 4.0% in North America. However, in 
certain sub-populations, the relative contribution of infections as a cause of cancer is much higher 
regardless of geographical region. In particular, people living with human immunodeficiency virus 
(HIV) infection (PLHIV) have strongly increased risk for infection-related cancers; this is due largely 
to the immunosuppressive effects of HIV, which allow viruses to establish infection and persist over 
time. In the United States during 1991-1995, prior to the introduction of effective antiretroviral 
therapy (eART), the rate of Kaposi sarcoma was increased 2800-fold in PLHIV, non-Hodgkin 
lymphoma 10-fold, and cervical cancer 3-fold.3 These three cancers were considered to define the 
onset of acquired immunodeficiency syndrome (AIDS), but increased risk in PLHIV spans the 
spectrum of infection-related cancers, with notable increases continuing to persist for anal cancer, 
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Hodgkin lymphoma, oral cavity/oropharyngeal cancer, and liver cancer.4,5 Due partly to increased 
smoking prevalence, the incidence of lung cancer is also increased 2-fold in PLHIV.4,6  
Since the introduction of eART in 1996, the epidemiology of cancer among PLHIV has shifted 
in multiple ways. PLHIV now live much longer lives, which has lead to substantial growth in the size 
of the HIV population as well as a shift toward older ages.7 Concurrently, since HIV treatment allows 
more effective immunologic control of viruses, the number of AIDS-defining cancers (all caused by 
viruses) have decreased over time while the number of non-AIDS-defining cancers has grown 
substantially.7 In 2010, an estimated 7,760 cancers occurred among PLHIV in the U.S., of which 
3,920 were in addition to those that would be expected if PLHIV had the same cancer rates as the 
general U.S. population (i.e., excess cancers).5 The most common types of excess cancer were non-
Hodgkin lymphoma, Kaposi sarcoma, lung cancer, and anal cancer, and the majority of excess 
cancers occurred among men who have sex with men (MSM). 
In the U.S. general population, individuals who are former or current tobacco smokers (i.e., 
ever-smokers) represent another important population at high risk for cancer. The Centers for 
Disease Control and Prevention (CDC) estimates that 17% of adult men and 14% of adult women 
currently smoke cigarettes, with prevalence higher among those with lower educational attainment, 
living in poverty, and living in certain states (notably West Virginia, Kentucky, and Arkansas).8 
Cigarette smoking is by far the most important cause of lung cancer, accounting for 80% of cases.1 
As a result, lung cancer has been the most common cause of cancer death in the U.S. since the 1950s 
(for men) and 1980s (for women), and in 2017, lung cancer caused 27% of cancer deaths in males 
and 25% in females. Encouragingly, U.S. lung cancer death rates have declined substantially since 
their peak in the 1990s (men) and 2000s (women) due to reductions in smoking. The 5-year relative 
survival for lung cancer is low, ranging from 55% for localized-stage cases to 28% for regional-stage 
cases to only 4% for distant-stage cases.9 Since 57% of cases are diagnosed at distant stage, 22% at 
regional stage, and only 16% at localized stage, improving methods for early detection (i.e., 
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identifying lung cancer at earlier stages when survival is higher) is a promising approach for 
decreasing lung cancer death rates.1,9 
 
1.2  Cancer Screening as a Tool to Reduce Cancer Burden 
The term “screening” is often used synonymously with the term “early detection.” Put simply, 
the goal of cancer screening is to identify cancer, or pre-cancerous lesions, at earlier stages when they 
can be more easily treated. Identifying cancer before it causes symptoms can reduce morbidity due to 
cancer or its treatment and prevent ultimate death from cancer. For some types of cancer, the goal of 
screening is largely to identify and remove pre-cancerous lesions, thus preventing cancer from 
occurring altogether. Such screening scenarios include cytology screening for cervical cancer (which 
identifies cervical intraepithelial neoplasia [CIN] precancerous lesions) and colonoscopy screening for 
colorectal cancer, which identifies precancerous adenomas. A relatively new screening setting that 
identifies pre-cancers is cytology screening for anal cancer, which is analogous to cervical cancer 
screening but occurs at the anus and is usually considered only for men who have sex with men 
(MSM). Other screening scenarios do not detect pre-cancerous lesions but aim to detect early-stage 
invasive cancer. These include mammography screening for breast cancer and low-dose computed 
tomography (CT) screening for lung cancer. 
The ongoing development of more sensitive technologies for early detection presents both 
opportunities and challenges for modern-day cancer screening. For example, using HPV testing for 
cervical cancer screening gives a very sensitive test, but required the development of appropriate 
management algorithms for women who are HPV-positive but still at low risk of cervical cancer.10 
CT screening has recently emerged as a sensitive tool for identifying lung cancer at earlier stages 
among heavy smokers, but because CT screening detects many lung nodules that are not malignant, 
reducing the rate of false-positive screens and the burden of associated follow-up is a persistent 
challenge.11–13  
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1.3  Precision Medicine and Cancer Screening 
In his State of the Union Address on January 20, 2015, President Barack Obama announced a 
research initiative to “accelerate progress toward a new era of precision medicine.”14 Precision 
medicine was defined broadly as “prevention and treatment strategies that take individual variability 
into account.” While the canonical example of precision medicine is the tailoring of cancer 
treatments based on particular tumor mutations, researchers have increasingly applied concepts of 
precision or personalization more broadly, including in the setting of cancer prevention and 
control.15–17 
Cancer screening has important benefits, namely the prevention of morbidity and mortality 
due to cancer and its treatment. However, screening also causes harms including overtreatment, false 
findings, psychological distress, and financial costs. Recently, the application of ideas and approaches 
within the realm of precision medicine has emerged as a way to find the appropriate balance of these 
benefits and harms.16,18,19 In particular, risk-tailored methods use an individual’s predicted cancer risk 
to determine whether, at what ages, and how often individuals should be screened; these methods are 
particularly relevant in cervical and lung cancer screening.10,20,21 Underlying risk-tailored approaches is 
the principle of “equal management of equal risks,” which posits that two groups at approximately 
equal cancer/precancer risk should be screened and managed in the same way.10 Precision 
approaches in the setting of cancer screening continue to gain traction: they were the subject of a 
2015 National Cancer Institute (NCI) symposium22 and are now considered a key tool for reducing 
cancer overdiagnosis and overtreatment.23 
 
 
1.4  HPV as a Cause of Cancer in People Living With HIV 
Human papillomaviruses (HPVs) are DNA viruses that infect squamous epithelia.24 Though 
there are over 100 distinct sub-types of HPV, only thirteen are classified as carcinogenic (“high-
risk”), most notably HPV16.25 HPV causes multiple anogenital cancers, including virtually all cervical 
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cancers and most anal cancers, as well as a subset of oropharyngeal cancers.2 Oncoproteins encoded 
by high-risk HPVs, namely E6 and E7, enable cancer development by promoting virus replication 
and immortalization of the human cell: E6 binds to and inactivates the tumor suppressor protein 
p53, while E7 binds to the tumor suppressor protein Rb.24 In essence, E6 disrupts cell cycle control, 
and then E7 allows the cell to replicate despite damaged DNA. Earlier in this process, the integration 
of HPV into the host DNA is thought to be a key step in carcinogenesis.   
Cancers caused by HPV are of particular concern in immunosuppressed individuals, 
particularly PLHIV. In the era of eART, as PLHIV are living longer and growing in number,26,27 
cancer is an increasing problem.7,28,29 Higher risks for all infection-related cancers in PLHIV, 
including HPV-related cancers, result from immunosuppression that allows oncogenic viruses to 
establish infection, persist, and cause cancer.30 HPV causes a substantial fraction of cancers among 
PLHIV in the U.S., which are primarily cervical and anal cancers (Table 1.1).31 In recent years, 
cervical cancer rates have declined but anal cancer is increasing,4 such that defining appropriate 
prevention strategies is challenging.29,31,32 Routine screening for these cancers will continue to be 
necessary for the foreseeable future, as HPV vaccination uptake has been gradual and its population 
effects will take many years to manifest.33 For males in particular, low vaccine uptake means that anal 
cancer rates will not decrease for many years.34 
A conceptual framework applying to Aims 1 and 2 of this dissertation is shown in Figure 1.1. 
In this framework, HPV-related cancers progress from normal tissue to HPV infection to precancer 
to cancer. Each transition can be affected by many risk factors, which include HIV-related 
immunosuppression and HPV genotype. Removal of precancers can prevent cancers from occurring. 
The results of a cytology screen at the cervix or anus can be used, along with additional risk factor 
information, to estimate an individual’s precancer/cancer risk. For those at high risk, referral to 
colposcopy (cervix) or anoscopy (anus) should be considered to detect and remove precancers. For 
those at low risk, the interval before returning to re-screening should be optimized (risk-tailored). For 
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those at intermediate or unclear risk, more information should be considered, such as a repeat 
cytology screen or HPV test. 
 
1.5  Cervical Cancer Screening in Women Living with HIV 
Cervical cancer risk among WLHIV was strongly elevated early in the U.S. HIV epidemic,35 
but has substantially declined4 and is now similar to the general population.36 I recently led a study 
showing that only 50 excess cervical cancers occurred in WLHIV in the U.S. in 2010,5 contradicting 
the notion that large numbers of excess cases continue to support aggressive screening for WLHIV 
(Table 1.1). 
Screening with pap cytology, combined with colposcopy to diagnose and remove precancers, 
has dramatically reduced cervical cancer.37 However, cytology screening also causes harms including 
vaginal bleeding, pain, infection, and psychological distress.38 Based largely on a risk benchmarking 
analysis,10 updated general population guidelines now suggest a 3-year interval after normal cytology 
before a woman should return for re-screening.38 Even though their risk has declined, WLHIV are 
still recommended for annual screening,39 with some guidelines lengthening the interval after multiple 
normal screens.40 Guidelines for managing atypical squamous cell of unknown significance (ASC-US, 
i.e., borderline) cytology in WLHIV are inconsistent: some recommend direct referral to colposcopy, 
while others include WLHIV in general population guidelines (HPV test triage or 6-12 month return 
for re-screening).39–41 
One reason for screening uncertainties in WLHIV is that most studies compare precancer risk 
among WLHIV to women who are HIV-negative but still at high HPV risk.42–44 Since guidelines are 
based on the level of risk in the general population, such comparisons are difficult to translate into 
practice. Therefore, my first dissertation aim analyzed data from the Women’s Interagency HIV 
Study (WIHS) to determine whether WLHIV have similar risks of cervical precancer after normal 
and ASC-US cytology compared to published risks in general population women, which would 
support longer screening intervals and less aggressive management. We hypothesized that, after 
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normal cytology, WLHIV with high CD4 cell counts have similar 3-year cervical precancer risk to 
general population women, while WLHIV with low CD4 cell counts have higher risk. After ASC-US 
cytology, we hypothesized that WLHIV regardless of CD4 count have similar 3-year precancer risk 
to general population women. 
 
1.6  Anal Cancer Screening in Men Who Have Sex With Men 
Anal cancer is relatively rare in the United States general population (1.8 per 100,000),45,46 
though rates are increasing.47 Incidence among HIV-MSM is extremely high (131 per 100,000)48 
because of HPV exposure during anal sex combined with immunosuppression. In 2010, 
approximately 740 excess anal cancers occurred among PLHIV in the U.S. (Table 1), the vast 
majority in HIV-MSM.5 This number is growing due to increasing anal cancer incidence4 and HIV 
population size.7 Anal cancer is also a concern for HIV-uninfected MSM.49,50 
Due to this disease burden, there is urgent demand for effective anal cancer screening for 
HIV-MSM.32,51,52 The leading strategy is anal cytology with referral to high-resolution anoscopy 
(HRA). This strategy is analogous to cervical cytology and colposcopy, but is severely under-
researched.51,53,54 Thus, despite frequent mention that anal cytology should be considered for HIV-
MSM, no national or international guidelines exist,50 and some recommend that all HIV-MSM should 
simply have annual HRA.55 
However, exploiting the utility of cytology alone is extremely important. While cytology has 
high acceptability among MSM,56,57 HRA is painful, burdensome, and has a shortage of providers. 
Avoiding unnecessary treatment of anal precancer is critical, because (1) treatment of anal precancer 
has harmful sequelae, (2) anal precancer appears less likely than cervical precancer to progress,58 and 
(3) evidence does not yet convincingly show that treating anal precancer is effective in preventing 
cancer.59–62 
One challenge facing anal cytology is that its repeatability is not described. At the cervix, 
repeat cytology is used in screening algorithms,40,63 but the repeatability of anal cytology has not been 
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assessed or associated with precancer risk. Therefore, my second aim analyzed data from the 
Multicenter AIDS Cohort Study (MACS) to quantify the proportions of HIV-positive MSM who 
have a pattern of consistently negative annual anal cytology or a pattern of consistently abnormal 
cytology over 3 years, and described demographic, clinical, and behavioral characteristics associated 
with these patterns. We hypothesized that more than 30% of HIV-positive MSM have a pattern of 
consistently normal anal cytology and that less than 15% have a pattern of consistently abnormal 
cytology, and that men with consistently abnormal cytology are more likely to have low CD4 counts 
and more sexual partners compared to men with consistently normal cytology. Among HIV-negative 
men, among whom only 2 cytology results are typically available, we also quantified transition 
probabilities between one cytology result (e.g., negative) to another (e.g., abnormal) and compared 
these to those observed among HIV-positive MSM. 
 
1.7  Lung Cancer Screening in Heavy Smokers 
Another important population at high risk for cancer in the U.S. – and one much larger than 
the HIV-infected population – is individuals with a current or past history of heavy smoking. 
Cigarette smoking causes lung cancer by exposing the smoker to multiple carcinogenic chemicals, by 
increasing the frequency of DNA adducts with these carcinogens via metabolic activation or other 
pathways, by promoting the expression of tumor suppressor genes, and by activating signal 
transduction pathways that allow the survival of damaged epithelial cells.64 Excess lung cancer risk 
declines after cessation of smoking, but does not disappear,65 and achieving widespread success in 
smoking cessation remains an unrealized goal.66–69 
Recently, lung cancer screening has emerged as a new tool to reduce lung cancer mortality 
among current or former heavy smokers. The National Lung Screening Trial (NLST) primary results 
were published in 2011, demonstrating a 20% reduction in lung cancer mortality with annual 
screening by low-dose CT as compared to chest radiography (which has been shown to have no 
effect on lung cancer mortality).11,70 Based on the NLST results, the U.S. Preventive Services Task 
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Force now recommends annual CT screening for adults aged 55 to 80 years who have a 30 pack-year 
smoking history and either currently smoke or have quit within the past 15 years.71 However, 
subsequent analyses of NLST data have demonstrated that the benefit of CT screening was 
concentrated in those at highest predicted risk of lung cancer,72 and that selecting individuals for 
screening based on this individual risk (calculated using detailed risk models) might improve the 
effectiveness, efficiency, and cost-effectiveness of screening programs.21,73,74 
A major challenge facing CT screening programs is high rates of false-positive screens and a 
large burden of associated diagnostic workup. Thus, there is substantial interest in identifying 
individuals who can safely lengthen screening intervals beyond 1 year, which could reduce the 
number of false-positive screens in a screening program.75–78 Such an approach would require that 
individual lung cancer risk, which can currently be calculated prior to screening using one of multiple 
validated risk models, be updated once CT screening results are known. Therefore, my third aim 
developed a model that calculates how individual lung cancer risk evolved during annual CT 
screening in the NLST. This model a) quantifies the effect of CT findings on future lung cancer risk 
and b) identifies individuals who might be candidates for extending screening intervals beyond 1 year.  
We hypothesized that risk of lung cancer within a CT screening program continues to depend on 
pre-screening (i.e., smoking-related) risk factors, but is also modified by CT findings. In addition, we 
hypothesized that those with a false-positive CT screening result have higher future lung cancer risk 
than those with a negative result, and that this risk can be further stratified by incorporating detailed 
features identified on CT.  
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1.8  Tables and Figures 
 
 
Table 1.1: Descriptive epidemiology of cervical and anal cancers among people living with HIV in the United 
States 
Cancer type High-risk group Incidence increase Incidence trend Excess cases, 2010 (N) 
Cervix HIV+ women 4-fold4 Decreasing4 505 
Anus HIV+ MSM 80-fold48 Increasing4 ~7005 
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Chapter 2:  Cervical Cancer Screening Intervals and 
Management for Women Living with HIV: A Risk 
Benchmarking Approach 
 
2.1  Abstract 
 
Objective: We suggested cervical cancer screening strategies for women living with HIV (WLHIV) 
by comparing their precancer risks to general population women, and then compared our suggestions 
to current CDC guidelines. 
 
Design: We compared risks of biopsy-confirmed cervical high-grade squamous intraepithelial 
neoplasia or worse (bHSIL+), calculated among WLHIV in the Women’s Interagency HIV Study, to 
“risk benchmarks” for specific management strategies in the general population.  
 
Methods: We applied parametric survival models among 2,423 WLHIV with negative or ASC-US 
cytology during 2000-2015. Separately, we synthesized published general population bHSIL+ risks to 
generate 3-year risk benchmarks for a 3-year return (after negative cytology, i.e., “re-screening 
threshold”), 6-12-month return (ASC-US), and immediate colposcopy (LSIL). 
 
Results: Average 3-year bHSIL+ risks among general population women (“risk benchmarks”) were 
0.69% for a 3-year return (after negative cytology), 8.8% for a 6-12-month return (after ASC-US), 
and 14.4% for colposcopy (after LSIL). Most CDC guidelines for WLHIV were supported by 
comparing risks in WLHIV to these benchmarks, including: a 3-year return after three negative 
cytology tests or a negative cytology/oncHPV co-test with CD4≥500 (all 3y-risks≤1.3%); a 1-year 
return after negative cytology with either positive oncHPV co-test (1y-risk=1.0%) or CD4<500 (1y-
risk=1.1%); and a 6-12-month return after ASC-US (3y-risk=8.2% if CD4≥500; 10.4% if CD4=350-
499). Other suggestions differed modestly from current guidelines, including colposcopy (vs. 6-12mo 
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return) for WLHIV with ASC-US and CD4<350 (3y-risk=16.4%) and a lengthened 2-year (vs. 1-
year) interval for WLHIV with CD4≥500 after negative cytology (2y-risk=0.98%).   
 
Conclusions: Current cervical cancer screening guidelines for WLHIV are largely appropriate. CD4 
count may inform risk-tailored strategies.  
 
2.2  Introduction 
 Women living with human immunodeficiency virus (WLHIV) are at elevated risk of cervical 
cancer and precancer.5,79,80 This risk has declined in recent years, possibly due to improvements in 
effective antiretroviral therapy (eART) or cervical cancer screening.4,36,81 Cervical cancer/precancer 
risks increase with diminishing immune status among WLHIV, even when comparing women with 
the same result from a cytology or oncogenic human papillomavirus (oncHPV) test.43,79,80,63,82–84 
To prevent cervical cancer in the general population, the U.S. Preventive Services Task 
Force (USPSTF) and the American Cancer Society (ACS) recommend screening by cytology alone 
or, in women ages 30 years and above, screening either by cytology alone or with oncHPV co-
testing.38,85 For WLHIV, the Centers for Disease Control and Prevention (CDC) issues screening and 
management guidelines that employ the same modalities in the same age groups, but reflect that 
WLHIV are at higher cervical cancer risk.40 For example, after a negative co-test (i.e., a concurrent 
cytologic diagnosis within normal limits [negative cytology] and negative oncHPV test), the USPSTF 
and ACS recommendation for HIV-uninfected women is a 5-year return, while the CDC 
recommends that WLHIV return for re-screening after 3 years.38,40,85 After negative cytology alone, 
suggested intervals are 3 years for HIV-uninfected women compared to 1 year for WLHIV. 
The CDC guidelines were influenced by data from the Women’s Interagency HIV Study 
(WIHS).36,42,43,80,63,84,86–89 In WIHS studies, WLHIV have been compared to a parallel group of HIV-
uninfected women who are at high risk of acquiring HIV.44 While these women are an appropriate 
reference for exploring causal effects of HIV, their cervical precancer risks may be higher than risks 
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in the general population, since HIV and cervical HPV have shared risk factors. Thus, from these 
studies, it is difficult to determine whether screening strategies for the general population can be 
applied to WLHIV. 
In this study, we aimed to describe the cervical cancer screening strategies suggested for 
WLHIV by an explicit comparison of their cervical precancer risks to true general population risks to 
which USPSTF and ACS guidelines are applied. To draw these comparisons, we used the framework 
of risk benchmarking, which was adopted during a 2012 conference to establish consensus 
management guidelines for abnormal cervical cancer screening tests in the general population.10,20,41 
In addition, because immunosuppression is strongly associated with cervical cancer/precancer risk in 
WLHIV,43,79,80,63,82–84 we considered CD4 count as a stratifying factor to explore potential 
opportunities for risk-tailored screening strategies. 
 
2.3  Methods 
Overall Approach 
 Risk benchmarking is used to ensure consistent management of individuals who are at 
similar risk of disease.10,20 In brief, a management strategy for a particular test result is chosen by 
calculating disease risk among patients with the test result, then comparing this to risks following 
other test results with well-established management guidelines (“risk benchmarks”). Then, the 
guideline associated with a similar risk is applied to the test result in question. For cervical cancer 
screening, guidelines in the general population are well established, based on large clinical trials and 
extensive observational or clinical cohort data. Appropriate data are less available in WLHIV, with 
the WIHS being one of few cohorts with adequate sample size and follow-up. Therefore, we first 
estimated risk benchmarks of biopsy-confirmed cervical high-grade squamous intraepithelial 
neoplasia or worse (bHSIL+) in the general population, and then assessed risks in the WIHS. 
Consistent with the approach used to incorporate oncHPV testing into current guidelines, 
we generated benchmarks for the levels of risk that have historically triggered each of the following 
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management strategies in the general population: a 3-year return for re-screening (this is the 
recommendation after negative cytology), a 6-12-month return (after atypical squamous cell of 
undetermined significance [ASC-US]), and immediate colposcopy (after low-grade squamous 
intraepithelial lesion [LSIL]).10,41 Then, for each result defined by cytology alone or 
cytology/oncHPV co-testing, we applied the strategy whose corresponding benchmark closely 
approximated the risk among WLHIV. 
To address questions regarding the interval between negative screens, we extended the 
existing framework of risk benchmarking. Specifically, since USPSTF and ACS guidelines 
recommend a 3-year return following negative cytology, we reasoned that the risk accumulated at 3 
years after negative cytology in the general population represents the threshold that triggers re-
screening. Therefore, we estimated risk benchmarks at 3 years, and defined the 3y-return benchmark 
as the re-screening threshold. Then, to identify the suggested return interval for WLHIV following a 
negative screen, we chose the annual time-point at which risk very closely approximated, or first 
exceeded, the 3y-return benchmark. For consistency, we also estimated risk benchmarks at 3 years 
for a 6-12mo return (after ASC-US) or immediate colposcopy (LSIL). 
Study Population 
We calculated risks among WLHIV in the WIHS, an observational cohort of women with 
and at risk for HIV (https://statepi.jhsph.edu/wihs/wordpress/). Enrollment occurred during 1994-
95, 2001-02, 2011-12, and 2013-15 at 11 study sites across the United States.44,90,91 Participants are 
screened every 6 months with cytology and are referred to colposcopy for ASC-US cytology or 
worse. HPV DNA testing of cervicovaginal lavage samples is also available at many visits from a 
previous HPV sub-study.42,43 Conventional single-slide testing92 and noncommercial type-specific 
HPV DNA L1 degenerate primer MY09/MY11/HMB01 polymerase chain reaction assays42 are used 
for cytology and HPV testing, respectively. We defined oncHPV positivity as the presence of any of 
the 13 oncogenic HPV types included in the Hybrid Capture II assay, which is commonly used in 
cervical cancer screening.93 
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 This analysis was restricted to the years 2000-2015 (to represent the current HIV treatment 
era) and to WLHIV aged 21-65 years old (ages when screening is recommended). We analyzed all 
participants from the different enrollment waves collectively, although bHSIL+ risk decreases with 
time in study.80 We excluded women with a history of hysterectomy prior to entry. We made no 
exclusions based on history of cervical precancer or its treatment, as we aimed to mimic a clinical 
care setting representing all WLHIV. Our study updates previous WIHS analyses36,42,43,80,63,84,86–89 by 
including new sites in the southern United States. The WIHS protocol was approved by institutional 
review boards at participating study sites. 
Calculation of Benchmarks and Risks 
 To generate risk benchmarks, we identified large published studies describing risks of 
bHSIL+ after negative, ASC-US, or LSIL cytology among general population women in usual care in 
the United States, and also included risks among WIHS HIV-uninfected women. We synthesized 
estimates across studies using unweighted linear regression models with random (study-specific) 
intercepts. For each cytology result, we calculated the corresponding risk benchmark by using the 
overall mean intercept and slope to predict risk at 3 years (further details in Supplementary Methods). 
Among WLHIV in the WIHS, we first analyzed bHSIL+ risk following a single cytology 
result, disregarding oncHPV results. We identified each eligible woman’s first cytology in 2000 
onward, then restricted to women with a negative or ASC-US result. We did not consider results of 
LSIL or worse. We identified each woman’s first occurrence of bHSIL+ following her entry cytology, 
then calculated follow-up time from cytology to the earliest of bHSIL+, age 66, or last screening 
follow-up (cytology or colposcopy). We used parametric survival models to estimate annual 
cumulative incidence of bHSIL+ from 1 to 5 years. We truncated follow-up at 5 years to improve the 
fit of parametric models to nonparametric estimates (further details in Supplementary Methods). 
For risk following combined cytology and oncHPV (co-testing) results, after restricting to 
women with a concurrent oncHPV test result, we also restricted to WLHIV aged 30-65 years to 
maintain consistency with age guidelines for co-testing.38,40,85 Where possible, for women without a 
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concurrent oncHPV result, we analyzed the next visit with both cytology and oncHPV results 
available (N=93). 
We also analyzed risk following multiple consecutive negative cytology results, which by 
design were obtained every 6 months. Among women with negative cytology, we further restricted to 
women whose second, and then third, cytology was negative. We did not consider pre-2000 results. 
In each case, we calculated follow-up from the final cytology, excluding women with a gap of 4 or 
more years between consecutive results (N=8 and N=6 after 2 and 3 negative results, respectively). 
We used biopsy-confirmed cervical intraepithelial neoplasia grade 2 or higher (CIN2+)94 as 
our primary bHSIL+ endpoint, given the more limited number of CIN grade 3 or higher (CIN3+). 
However, we repeated all analyses using CIN3+, as this is a more specific precancer endpoint. For 
analyses with larger numbers of women, and thus better power to evaluate the effect of CD4 cell 
count (analyses based on cytology only [disregarding oncHPV], and women with a cytology-
negative/oncHPV-negative co-test), we stratified by CD4 cell count at the time of cytology using a 
standard threshold that was near the median (≥500 or <500 cells/μL). Consistent with other 
benchmarking studies, we considered risk benchmarks to be measured without error,10,95,96 but 
estimated 95% confidence intervals [CIs] for relevant bHSIL+ risks among WLHIV. We calculated 
two-sided Wald p-values for selected statistical comparisons.  
 
2.4  Results 
 
The 3-year bHSIL+ (CIN2+) risk benchmark for a suggested 3-year return to screening was 
0.69% (Figure 2.1, Table 2.1) based on 4 estimates of risk after negative cytology among general 
population women10,97,98 and HIV-uninfected WIHS women. The benchmarks warranting a 6-12mo 
return and immediate colposcopy were 8.8% (based on 4 studies of risk after ASC-US) and 14.4% 
(based on 2 studies of risk after LSIL), respectively. 
 For the cytology-only analysis, we analyzed 2,423 WLHIV in the WIHS, including 2,049 with 
negative cytology and 374 with ASC-US cytology (Table 2.2). Most women with negative cytology 
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were non-Hispanic Black (61%), had taken ART (80%), and were aged 30-49 years (74%) at the time 
of cytology. Approximately half (51%) of women with negative cytology had a CD4≥500 at the time 
of cytology, compared to only 29% of women with ASC-US cytology (p<0.001). Most women 
contributed at least 5 years of follow-up. For risk following co-test results, we analyzed 1,439 
WLHIV including: 1,070 cytology-negative/oncHPV-negative, 124 cytology-negative/oncHPV-
positive, 163 ASC-US/oncHPV-negative, and 82 ASC-US/oncHPV-positive. 
Negative cytology, with or without oncHPV testing 
 We compared bHSIL+ risk among WLHIV with negative cytology to the general population 
benchmarks. After a single negative cytology result (Figure 2.1A), WLHIV with CD4≥500 (measured 
concurrently with cytology) first exceeded the 3y-return benchmark (0.69%) at 2 years (2-year 
risk=0.98% [95%CI 0.44-1.5%]). The 3-year risk among these women (1.5%) was statistically 
significantly higher than the benchmark (p=0.019). Among WLHIV with a CD4<500, risk first 
exceeded the benchmark at 1 year (1-year risk=1.1% [95%CI 0.51-1.6%]), and the 2-year risk (2.0%) 
was statistically significantly higher than the benchmark (p<0.001). This suggests that after a single 
negative cytology, WLHIV with CD4≥500 may be able to safely return for re-screening in 2 years, 
whereas risk among women with CD4<500 warrants a 1-year return. 
Risks were lower among women with a concurrent negative cytology and oncHPV test 
(negative co-test, Figure 2.1B). For WLHIV with CD4≥500, risk first exceeded the 0.69% 3y-return 
benchmark at 3 years (3-year risk=0.94 [95%CI 0.21-1.7%]). Among WLHIV with CD4<500, 1- and 
2-year risks were 0.66% (95%CI 0.08-1.2%) and 1.3% (95% CI 0.47-2.1%), respectively, with 3-year 
risk (1.9% [95%CI 0.87-2.9%]) remaining substantially below the threshold for a 6-12 month return 
(8.8%). In further analysis, we identified that risk was strongly elevated among the small group of 
WLHIV with CD4<200 (1-year risk=1.6%), but more moderate among the larger group with CD4 
200-499 (1- and 2-year risks=0.33% and 0.90%, respectively). These data thus suggest that risk is low 
following a negative co-test, consistent with a suggested 3-year return in WLHIV with CD4>500 and 
possibly a 2-year return in WLHIV with CD4<500. 
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Finally, when negative cytology was combined with a positive oncHPV co-test (Figure 2.2C), 
risk among all WLHIV exceeded the 3y-return benchmark at 1 year (1-year risk=1.0% [95%CI 0-
2.4%]), suggesting a 1-year return. 
ASC-US cytology, with or without oncHPV testing 
 After ASC-US cytology (Figure 2.3A), the 3-year bHSIL+ risk among WLHIV with 
CD4≥500 was 8.2% (95%CI 3.3-13.2%), approximating the 6-12mo return benchmark of 8.8%. 
Women with CD4<500 appeared to have a higher 3-year risk of 14.2% (95%CI 10.2-18.2%), 
approximating the colposcopy benchmark of 14.4%, but this was driven by high risk among WLHIV 
with CD4<350 (3-year risk=16.4% [95%CI 11.1-21.7%], Figure 2.4). This suggests that appropriate 
management strategies for women with ASC-US and unknown oncHPV status are repeat cytology in 
6-12mo for women with current CD4≥350, as currently recommended. For WLHIV with CD4<350, 
it may be appropriate to consider immediate colposcopy. 
 Following ASC-US cytology combined with a negative oncHPV test (Figure 2.3B), 3-year 
risk among all WLHIV was 6.5% (95%CI 2.9-10.1%). Although this is below the 8.8% benchmark 
for a 6-12mo return, the 1-year risk was much higher than the 3y-return benchmark (1-year 
risk=4.3% [95%CI 1.6-6.9%] vs. 0.69% benchmark). When ASC-US cytology occurred instead with a 
positive oncHPV test (Figure 2.3C), the 3-year risk among all WLHIV was 14.6% (95%CI 7.4-
21.8%), approximating the benchmark for colposcopy (14.4%). Taken together, this supports a 6-
12mo return following an ASC-US/oncHPV-negative co-test, but immediate colposcopy following 
an ASC-US/oncHPV-positive co-test. 
Consecutive negative cytology results 
 When oncHPV testing is not employed, guidelines have used consecutive negative cytology 
results to identify women at low risk.40 Therefore, we compared bHSIL+ risk after multiple negative 
cytology results (spaced by approximately 6 months) to the 3y-return risk benchmark. After 3 
consecutive negative cytology results, for WLHIV with CD4≥500 (measured at the third cytology), 
the 3y-return benchmark (0.69%) was first exceeded at 3 years (3y risk=0.96% [95%CI 0.31-1.6%], 
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Figure 2.5A). For WLHIV with CD4<500, risk appeared slightly higher, matching the benchmark at 
2 years (2y risk=0.68% [95%CI 0.12-1.2%], Figure 2.5B); however, confidence intervals were wide 
and also included the benchmark at 3 years. This suggests that risk after 3 consecutive negative 
cytology results is low for all women, consistent with a suggested return after 3 years in women with 
CD4≥500. For women with CD4<500, a return after 2 years might be considered. Of note, among 
women with CD4≥500, each additional negative cytology result suggested reduced risk (Figure 2.5A), 
while among women with CD4<500, risks after 2 and 3 negative results were equivalent (Figure 
2.5B). 
Results based on outcome of CIN3+ 
We assessed the sensitivity of our results to our definition of bHSIL+ by repeating our analysis 
using CIN3+ instead of CIN2+ (Figure 2.6, Figure 2.7, Figure 2.8, Figure 2.9, Table 2.4). The risk 
benchmarks for CIN3+ included the same studies as for CIN2+ (Table 2.1) and were 0.36% (3y 
return), 3.4% (6-12mo return), and 4.7% (colposcopy) (Figure 2.6). Confidence intervals around 
CIN3+ risk estimates were very wide, and we disregarded them to identify suggested strategies. One 
analysis had modestly different inferences (concurrent negative cytology and oncHPV co-test), where 
benchmarks were reached more quickly using CIN3+ (Table 2.3, Table 2.4). Apart from this, 
strategies suggested by CIN3+ were the same as for CIN2+. 
 
2.5  Discussion 
 In this study, we explored the cervical cancer screening strategies suggested by an explicit 
comparison of precancer risks between WLHIV and general population women. Although our 
approach differed from prior studies in multiple ways, including restriction to the current era of HIV 
treatment (2000 or later), our results largely supported existing cervical cancer screening guidelines 
for WLHIV40 (Table 2.3). We also explored the utility of CD4 cell count for stratifying bHSIL+ risks 
among WLHIV. Although we could not always estimate risks with sufficient precision to rule out 
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alternative strategies, we identified some scenarios in which CD4 count could be further explored for 
tailoring screening intervals or management strategies.  
Our analysis identified that some WLHIV have low bHSIL+ risks. For WLHIV with 
negative cytology, a negative oncHPV co-test, and a CD4≥500, as well as for WLHIV with 3 
consecutive negative cytology results and a CD4≥500, risks of precancer were low (<1% at 3 years). 
While these risks were still modestly above the benchmark for a 3-year return (0.69%), their 
confidence intervals included this benchmark while definitively excluding the 6-12mo return 
benchmark of 8.8% (upper bounds≤1.7%). A previous study of co-test-negative WLHIV in the 
WIHS did not identify any cases of bHSIL+ over 5 years, but did suggest higher risk of low-grade 
SIL among WLHIV with lower CD4 counts.42 Our study, which includes larger numbers of WLHIV, 
suggests that some portion of these low-grade SIL will progress to high-grade SIL. 
Further, our results suggested that WLHIV with lower CD4 counts may benefit from more 
frequent screening than those with higher CD4 counts. Even when co-testing is used, our approach 
suggested WLHIV with a CD4<500 may have higher bHSIL risk than WLHIV with CD4≥500. The 
small group of WLHIV with CD4<200 had particularly high risk, but it is unlikely that frequent 
screening would be beneficial in these women, who may have multiple medical problems and/or 
short life expectancy. When negative cytology was found concurrently with oncHPV, we found that a 
1-year return is appropriate, consistent with current guidelines.40 A previous WIHS study supports 
the additional guideline for colposcopy if HPV16 or HPV18 is present;43 however, we did not have 
sufficient post-2000 data to confirm this strategy. Following ASC-US cytology, which is common 
among WLHIV,99 guidelines currently recommend colposcopy only if oncHPV is concurrently 
detected. Our analysis suggested that when oncHPV is unknown, a CD4<350 indicates similarly high 
risk, whereas women with higher CD4 counts can safely return for repeated screening within 1 year. 
In the United States and other high-resource settings, the proportion of women with low 
CD4 counts has decreased as more WLHIV are on eART.100 However, in low-resource settings, any 
recommendation for more aggressive screening among WLHIV with low CD4 counts could affect a 
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large proportion of WLHIV.101,102 It is unclear whether eART itself (independent of its effect on 
CD4 count) directly impacts bHSIL+ incidence,40,89,103 and our study did not stratify by eART status. 
However, our findings do support guidelines recommending that all WLHIV be offered eART,104 
which increases CD4 counts and thus may reduce bHSIL+ risks.89 As in the general population, HPV 
vaccination will also continue to influence the balance of benefits and harms for cervical cancer 
screening in WLHIV.33  
 WLHIV constitute a special population that is at elevated risk for cervical cancer, but is also 
subject to a high burden of medical screening and tests. We explored screening strategies for WLHIV 
using an approach based on risk benchmarking, which provides a framework for ensuring that similar 
management is applied to similar risks. We used the best available data from a large and established 
cohort study to evaluate risks among WLHIV, and applied parametric survival models so that risk 
estimates did not change sharply when outcomes were sparse. Though many studies have examined 
cervical cancer screening in the WIHS, our study complements prior work by including additional 
data from new WIHS cohorts, restricting to the current eART era, and employing benchmarks that 
reflect true general population risks. Our selection of CD4 cell count as an a priori factor for 
stratification of bHSIL+ risks is supported by extensive research in the WIHS and other 
studies.43,79,80,63,82–84 
Our approach required that we apply risk benchmarking in two novel ways. First, we 
compared risks across populations (the WIHS and general population studies) that differ with regard 
to frequency of screening, bHSIL+ outcome ascertainment, data quality, and statistical methods. 
Second, the time-to-benchmark approach that we used to suggest screening intervals is a novel 
application that was not previously established. Consistent with other benchmarking studies, we 
considered risk benchmarks to be measured without error,10,95,96 and we set screening intervals 
according to when these benchmarks were met or exceeded. However, with the first benchmark at 
0.69% (3-year return), it could be argued that a higher threshold should be used before shortening 
the screening interval from 3 years, as the second benchmark was much higher (8.8% for 6-12mo 
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return) – a matter for guideline committees to consider. Our risk benchmark estimates may be 
sensitive to the inclusion or exclusion of studies (e.g., non-U.S. studies were excluded). However, we 
believe that our approach of synthesizing risks from robust studies yielded the best available 
benchmarks to reflect the risk levels associated with general population screening guidelines in the 
United States. Finally, while we have identified some opportunities for tailoring screening by CD4 
count at the time of cytology/HPV testing, there are other potential stratification factors that we did 
not consider. For example, bHSIL+ risk is likely affected by a woman’s cumulative history of 
immunosuppression (including the nadir CD4 value and duration of immunosuppression), and 
women with a previous history of bHSIL+ (with or without treatment) may have higher risks and 
thus require more individualized management. Further, risk may also vary by age, particularly in 
unscreened women. 
Considerable research has evaluated cervical HPV infection and abnormalities among 
WLHIV, but few studies have explicitly compared risks between WLHIV and general population 
women within a systematic framework oriented toward screening guidelines. Despite major 
differences from prior work, our analysis largely supported existing screening guidelines for WLHIV. 
We additionally found that CD4 cell count, measured at the time of a cervical cancer screening test, 
may have utility to inform some decisions about screening intervals and management. The impetus to 
include additional strata to refine screening practices, though, must be balanced against the goal to 
simplify and harmonize clinical guidelines. As HIV therapies and cervical cancer screening continue 
to evolve, optimal management will require ongoing evaluation of appropriate screening strategies in 
this population. The novel benchmarking approach used in this study could be a helpful new tool in 
this process.   
 
2.6  Supplementary Methods 
Generation of Risk Benchmarks 
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Our goal was to estimate risk benchmarks that summarize the range of bHSIL+ risks to 
which guidelines are applied in the general population, thus allowing bHSIL+ risks among women 
living with HIV (WLHIV) to be placed in the context of general population risks. Therefore, we 
reviewed the literature for published studies describing risks of CIN2+ and/or CIN3+ after negative, 
ASC-US, or LSIL cytology among general population women in the United States. We included large 
studies taking place in a usual care setting that presented numerical risk percentages between 1 and 5 
years following cytology. We required that data analyzed in these studies extend beyond the year 
2000, to ensure overlap with our data for WLHIV. We also included risks generated using data from 
HIV-uninfected women in the Women’s Interagency HIV Study (WIHS), except for the LSIL 
(colposcopy) benchmarks, where we did not have sufficient data.  
We synthesized estimates across studies using mixed-effects linear regression models with 
random intercepts (for study) and fixed slopes, as random-slope models did not converge due to 
small numbers of clusters (studies). Although the change in risk over time is not precisely linear, this 
approach allowed us to adequately capture variation in risk within and between studies (Supplemental 
Figures 1 and 3). We did not weight the studies based on sample size, as we did not want the 
benchmarks to heavily reflect the largest studies. Instead, by using unweighted models, we aimed to 
reflect the variability in risks due to more substantive differences in study populations (e.g., 
demographic differences, screening programs) and analytical methods. 
We expect that the magnitude of our risk benchmarks might be sensitive to the inclusion or 
exclusion of different studies. For example, the risk benchmarks might differ if we included studies 
from other countries, particularly those with screening programs different than the United States. By 
themselves, some of the studies that we included would yield risks too low to compare to the 
WLHIV in WIHS (for example, risks are notably low in the Kaiser Permanente Northern California 
data 10), while others would yield risks too high (for example, the HIV-uninfected women in WIHS, 
because they are at elevated risk for HIV and therefore HPV). We believed it was important to 
include risks among HIV-uninfected women in the WIHS so that any unique aspects of the WIHS 
     25 
screening program (e.g., frequent screening and a low threshold for colposcopy referral) were 
represented. By synthesizing a diverse set of risks, we aimed to summarize the risks to which general 
population screening guidelines are applied in the United States. 
Calculation of bHSIL+ Risks in WLHIV 
To calculate bHSIL+ risks among WLHIV in the WIHS, we used parametric survival 
models. These models smooth over the sharp changes in risk that can result from non-parametric 
(e.g., Kaplan-Meier) approaches. Among each group of women defined by cytology result, HPV 
result, and CD4 cell count, we fit separate models based on the Weibull and log-normal distributions. 
We then chose one model for each group based on visual fit to Kaplan-Meier estimates and the 
Akaike information criterion (AIC), and used the resulting model to predict risk (i.e. cumulative 
incidence, or 1 – S(t)) at 1, 2, 3, 4, and 5 years. We generated the figures by smoothly connecting 
these annual risk estimates. 
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2.8  Tables and Figures 
 
Table 2.1 General population studies analyzed to generate risk benchmarks of cervical intraepithelial neoplasia 
(CIN) for comparison to risks in women living with HIV. 
  Study  
Characteristic 
Katki et al., J Low Genit 
Tract Dis 201310 
Gage et al., Cancer 
Epidemiol Biomark 
Prev 201698 
Castle et al., J Clin 
Oncol 2012*97 
Women’s Interagency 
HIV Study (WIHS)† 
Cytology results 
included in analysis 
Negative, ASC-US, LSIL 
Negative, ASC-US, 
LSIL 
Negative, ASC-US Negative, ASC-US 
Data type Usual care (HMO) Usual care (registry) Usual care (HMO) Cohort 
Sample size 965,360 452,045 19,512 1,018 
Timch e period 2003-2010 2007-2013 1989-2006 2000-2015 
Location Northern California New Mexico Portland, Oregon 
11 study sites in the 
United States 




27% age 21-29 
23% age 30-39 
23% age 40-49 
27% age 50-64 
Mean 35.8 
Median 34.0 
25% age 20-29 
32% age 30-39 
29% age 40-49 































Basis for both 
exclusion and 
censoring 
Basis for exclusion Basis for exclusion 
 
HMO, health maintenance organization; PI, Pacific Islander. Percentages may not sum exactly to 100% due to rounding. 
*Exact numerical risk estimates are not displayed in the figures in this study, but were provided by the publisher. 
†We analyzed data from HIV-uninfected women in the WIHS using the same methods described in this manuscript (see 
Methods). Women who seroconverted (became HIV-infected) during follow-up were censored at the time of 
seroconversion. 
‡Demographic characteristics listed from Katki et al., Lancet Oncol 2011.105 Estimates provided for race/ethnicity are 
based on a survey to which 49% of the population responded. 
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Table 2.2 Descriptive characteristics of 2,423 women living with HIV in the Women’s Interagency HIV Study 







Total 2,049 (100) 374 (100)  
oncHPV status   <0.001 
    Negative  1,247 (60.9) 191 (51.1)  
    Positive 159 (7.8) 103 (27.5)  
    Unknown 643 (31.4) 80 (21.4)  
Age, years   0.046 
    20-29 243 (11.9) 62 (16.6)  
    30-39 773 (37.7) 145 (38.8)  
    40-49 744 (36.3) 123 (32.9)  
    50 or older 289 (14.1) 44 (11.8)  
Race/ethnicity   0.66 
    Non-Hispanic Black 1,254 (61.2) 238 (63.6)  
    Non-Hispanic White 259 (12.6) 39 (10.4)  
    Hispanic 467 (22.8) 85 (22.7)  
    Other 69 (3.4) 12 (3.2)  
WIHS enrollment cohort   <0.001 
    1994-95 932 (45.5) 189 (50.5)  
    2001-02 509 (24.8) 116 (31.0)  
    2011-12 215 (10.5) 34 (9.1)  
    2013-15 393 (19.2) 35 (9.4)  
Current CD4 count (cells/μL)*   <0.001 
    ≥500 1,042 (50.9) 108 (28.9)  
    350-499 423 (20.6) 90 (24.1)  
    200-349 359 (17.5) 88 (23.5)  
    <200 203 (9.9) 87 (23.3)  
    Missing 22 (1.1) 1 (0.3)  
Smoking status†   0.07 
   Current smoker 1,118 (54.6) 184 (49.3)  
   Not a current smoker 930 (45.4) 189 (50.7)  
Ever ART    0.16 
    No 409 (20.0) 63 (16.8)  
    Yes 1,640 (80.0) 311 (83.2)  
Length of follow-up, years (median, IQR) 6.9 (1.6-12.9) 5.0 (1.6-12.8) 0.12 
 
ART, antiretroviral therapy; IQR, interquartile range. Percentages may not sum exactly to 100 due to rounding. 
*If CD4 count was missing, we used the most recent CD4 count measured prior to the time of cytology (N=36, 1.5%), 
allowing a gap of up to 2 years. 
†Missing for one woman. 
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Table 2.3 Summary of bHSIL+ (CIN2+) risks among women living with HIV and the cervical cancer screening 
strategies suggested by this risk benchmarking approach.  
Cytology HPV CD4 
Observed bHSIL+ (CIN2+) risk, % (95% CI) at: Risk-based 
strategy 
CDC 
guideline 1 year 2 years 3 years 
3 Negative Unknown 
≥500 0.11 (0-0.30) 0.45 (0.02-0.89) 0.96 (0.31-1.6) 3y return 
3y return 
<500 0.19 (0-0.46) 0.68 (0.12-1.2) 1.3 (0.52-2.1) 2-3y return 
Negative 
Negative 
≥500 0.20 (0-0.51) 0.53 (0-1.1) 0.94 (0.21-1.7) 3y return 
3y return 
<500 0.66 (0.08-1.2) 1.3 (0.47-2.1) 1.9 (0.87-2.9) 2y return* 
Unknown 
≥500 0.46 (0.10-0.81) 0.98 (0.44-1.5) 1.5 (0.83-2.3) 2y return 
1y return 
<500 1.1 (0.51-1.6) 2.0 (1.2-2.8) 2.9 (1.9-3.9) 1y return 
Positive Any 1.0 (0-2.4) 3.0 (0.40-5.5) 5.1 (1.7-8.6) 1y return 1y return.† 
ASC-US 
Negative Any 4.3 (1.6-6.9) 5.6 (2.4-8.8) 6.5 (2.9-10.1) 6-12mo return (Not stated) 
Unknown 
≥500 3.7 (0.62-6.7) 6.2 (2.2-10.2) 8.2 (3.3-13.2) 6-12mo return 
6-12mo 
return 
350-499 6.9 (2.4-11.4) 9.0 (3.4-14.4) 10.4 (4.3-16.5) 6-12mo return 
<350 8.9 (5.3-12.6) 13.1 (8.6-17.7) 16.4 (11.1-21.7) Colposcopy 
Positive Any 8.3 (3.2-13.3) 12.0 (5.7-18.2) 14.6 (7.4-21.8) Colposcopy Colposcopy 
 
Three-year risk benchmarks based on general population risks were 0.69% (3y return), 8.8% (6-12mo return), and 14.4% 
(colposcopy). Risks after combined cytology/HPV testing (co-testing) were calculated only among women aged 30 years 
and older, consistent with U.S. Preventive Services Task Force, American Cancer Society, and Centers for Disease Control 
and Prevention (CDC) guidelines. CD4 count was measured at the time of cytology/HPV testing. 
bHSIL+, biopsy-confirmed high grade squamous intraepithelial lesion or worse; CIN2+, cervical intraepithelial neoplasia 
grade 2 or higher; WLHIV, women living with HIV; CDC, Centers for Disease Control and Prevention. 
*We found that a 2-year return was more appropriate than a 1-year return for most women in this group (see Results).  
† Colposcopy if HPV16+ or HPV16/18+. We did not have sufficient data to evaluate this guideline. 
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Table 2.4 Summary of bHSIL+ (CIN3+) risks among women living with HIV and the cervical cancer screening 
strategies suggested by this risk benchmarking approach. 
Cytology HPV CD4* 
Observed bHSIL+ (CIN3+) risk, % (95% CI) at: Risk-based 
strategy 
CDC 
guideline 1 year 2 years 3 years 
3 Negative Unknown 
≥500 0.04 (0-0.15) 0.15 (0-0.41) 0.32 (0-0.70) 3y return 
3y return 
<500 0.15 (0-0.40) 0.39 (0-0.81) 0.65 (0.08-1.2) 2y return 
Negative 
Negative 
≥500 0.15 (0-0.43) 0.32 (0-0.74) 0.49 (0-1.03) 2y return 
3y return 
<500 0.32 (0-0.72) 0.80 (0.16-1.4) 1.3 (0.46-2.1) 1y return 
Unknown 
≥500 0.23 (0-0.48) 0.44 (0.08-0.81) 0.65 (0.18-1.12) 2y return 
1y return 
<500 0.40 (0.06-0.74) 0.84 (0.34-1.3) 1.3 (0.60-1.9) 1y return 
Positive Any 0.17 (0-0.69) 0.67 (0-1.9) 1.5 (0-3.3) 1y return 1y return* 
ASC-US 
Negative Any 1.7 (0.02-3.5) 2.3 (0.23-4.4) 2.7 (0.35-5.1) 6-12mo return (Not stated) 
Unknown 
≥500 1.5 (0-3.5) 2.5 (0-5.0) 3.2 (0.06-6.4) 6-12mo return 6-12mo 
return <500 4.0 (1.9-6.0) 5.4 (2.9-7.9) 6.4 (3.5-9.3) Colposcopy 
Positive Any 3.3 (0-6.7) 4.5 (0.46-8.5) 5.4 (0.75-10.0) Colposcopy Colposcopy 
 
Three-year risk benchmarks based on general population risks were 0.36% (3y return), 3.4% (6-12mo return), and 4.7% 
(colposcopy). Risks after combined cytology/HPV testing (co-testing) were calculated only among women aged 30 years 
and older, consistent with U.S. Preventive Services Task Force and American Cancer Society guidelines. CD4 count was 
measured at the time of cytology/HPV testing. 
bHSIL+, biopsy-confirmed high grade squamous intraepithelial lesion or worse; CIN3+, cervical intraepithelial neoplasia 
grade 3 or higher; WLHIV, women living with HIV; CDC, Centers for Disease Control and Prevention. 
* Colposcopy if HPV16+ or HPV16/18+*. We did not have sufficient data to evaluate this guideline. 
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Figure 2.1 Generation of bHSIL+ (CIN2+) risk benchmarks for a 3-year return (after negative cytology, panel A), 
a 6-12 month return (after ASC-US cytology, panel B), and immediate colposcopy (after LSIL cytology, panel C). 
Black lines depict summary risks generated by linear models with random intercepts, and black points indicate 
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Figure 2.2 Risk of cervical bHSIL+ (CIN2+) among 2,049 women living with HIV (WLHIV) following negative 
cytology, by CD4 cell count at the time of cytology and oncogenic HPV status, compared to general population 
risk benchmarks for recommending women be re-screened in 3 years (3y return) or 6-12 months (6-12mo return). 
The Figure includes panels for: any oncogenic HPV result (positive, negative or unknown) (panel A), oncHPV-
negative (panel B), or oncHPV-positive (panel C). Calculation of risks following a co-test result (panels B and C) 




Among WLHIV with negative cytology, there were 20 bHSIL+ (CIN2+) events over 5 years among 1,042 women with 
CD4≥500 and 33 events among 985 women with CD4<500. Among women with negative cytology and a negative 
oncHPV co-test, there were 9 bHSIL+ events among 511 women with CD4≥500 and 15 events among 553 women with 
CD4<500. Among women with negative cytology and a positive oncHPV co-test, there were 10 bHSIL+ events among 124 
women. CD4 cell count was measured at the time of cytology and was unknown for 22 women. 
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Figure 2.3 Risk of cervical bHSIL+ (CIN2+) among 374 women living with HIV (WLHIV) following ASC-US 
cytology, by CD4 cell count at the time of cytology and oncogenic HPV co-test status, compared to general 
population risk benchmarks for recommending women be re-screened in 3 years (3y return), 6-12 months (6-12mo 
return), or referred for immediate colposcopy. The Figure includes panels for: any oncogenic HPV result 
(positive, negative or unknown) (panel A), oncHPV-negative (panel B), or oncHPV-positive (panel C). 




Among WLHIV with ASC-US cytology, there were 10 bHSIL+ (CIN2+) events over 5 years among 108 women with 
CD4≥500 and 41 events among 265 women with CD4<500. Among women with ASC-US cytology and a negative HPV 
co-test, there were 12 bHSIL+ events among 163 women. Among women with ASC-US cytology and a positive HPV co-
test, there were 14 bHSIL+ events among 82 women. CD4 cell count was measured at the time of cytology and was 
unknown for 1 woman. 
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Figure 2.4 Risk of cervical bHSIL+ (CIN2+) among 374 women living with HIV (WLHIV) following ASC-US 
cytology, by CD4 cell count at the time of cytology, compared to general population risk benchmarks for 





Among WLHIV with ASC-US cytology, there were 10 bHSIL+ (CIN2+) events over 5 years among 108 women with 
CD4≥500, 10 events among 90 women with CD4 350-499, and 31 events among 175 women with CD4<350. CD4 cell 
count was measured at the time of cytology and was missing for 1 woman. 
  
     35 
Figure 2.5 Risk of cervical bHSIL+ (CIN2+) among women living with HIV (WLHIV) following 1, 2, or 3 
consecutive negative cytology results, by CD4 cell count at final cytology (≥500 panel A, <500 panel B), compared 
to a general population risk benchmark for recommending women be re-screened in 3 years (3y return). 
  
Among WLHIV with CD4≥500, there were 1,042, 846, and 716 women with 20, 14, and 12 bHSIL+ (CIN2+) events, 
respectively, for the analysis of 1, 2, and 3 consecutive negative cytology results. Among WLHIV with CD4<500, there 
were 985, 785, and 620 women with 33, 16, and 14 bHSIL+ events, respectively, for analysis of 1, 2, and 3 consecutive 
negative cytology results. 
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Figure 2.6 Generation of bHSIL+ (CIN3+) risk benchmarks for a 3y return (after negative cytology, panel A), a 6-
12mo return (after ASC-US cytology, panel B), and immediate colposcopy (after LSIL cytology, panel C). Black 
lines depict summary risks generated by linear models with random intercepts, and black points indicate the 3-
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Figure 2.7 Risk of cervical bHSIL+ (CIN3+) among 2,049 women living with HIV (WLHIV) following negative 
cytology, by CD4 cell count at the time of cytology and oncogenic HPV status, compared to general population 
risk benchmarks for recommending women be re-screened in 3 years (3y return) or 6-12 months (6-12mo return). 
The Figure includes panels for: any oncogenic HPV result (positive, negative or unknown) (panel A), oncHPV-
negative (panel B), or oncHPV-positive (panel C). Calculation of risks following a co-test result (panels B and C) 




Among WLHIV with negative cytology, there were 8 bHSIL+ (CIN3+) events over 5 years among 1,042 women with 
CD4≥500 and 15 events among 985 women with CD4<500.  Among women with negative cytology and a negative HPV 
co-test, there were 4 bHSIL+ events among 511 women with CD4≥500 and 11 events among 553 women with CD4<500.  
Among women with negative cytology and a positive HPV co-test, there were 4 bHSIL+ events among 120 women. CD4 
cell count was measured at the time of cytology and was unknown for 22 women. 
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Figure 2.8 Risk of cervical bHSIL+ (CIN3+) among 374 women living with HIV (WLHIV) following ASC-US 
cytology, by CD4 cell count at the time of cytology and oncogenic HPV co-test status, compared to general 
population risk benchmarks for recommending women be re-screened in 3 years (3y return), 6-12 months (6-12mo 
return), or referred immediately for colposcopy. The Figure includes panels for: any oncogenic HPV result 
(positive, negative or unknown) (panel A), oncHPV-negative (panel B), or oncHPV-positive (panel C). 





Among WLHIV with ASC-US cytology, there were 4 bHSIL+ (CIN3+) events over 5 years among 108 women with 
CD4≥500 and 18 events among 265 women with CD4<500. Among women with ASC-US cytology and a negative HPV 
co-test, there were 5 bHSIL+ events among 163 women. Among women with ASC-US cytology and a positive HPV co-
test, there were 5 bHSIL+ events among 82 women. CD4 cell count was measured at the time of cytology and was 
unknown for 1 woman. 
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Figure 2.9 Risk of cervical bHSIL+ (CIN3+) among women living with HIV (WLHIV) following 1, 2, or 3 
consecutive negative cytology results, by CD4 cell count at final cytology (≥500 panel A, <500 panel B), compared 




Among WLHIV with CD4≥500, there were 1,042, 846, and 716 women with 8, 5, and 4, bHSIL+ (CIN3+) events, 
respectively, for the analysis of 1, 2, and 3 consecutive negative cytology results. Among WLHIV with CD4<500, there 
were 985, 785, and 620 women with 15, 7, and 6, bHSIL+ events, respectively, for analysis of 1, 2, and 3 consecutive 
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Chapter 3: Patterns of Repeated Anal Cytology Testing among 
HIV-positive and HIV-negative Men who have Sex with 
Men 
 
3.1  Abstract 
 
Background: Men who have sex with men (MSM) are at increased risk for anal cancer. In cervical 
cancer screening, patterns of repeated cytology are used to identify low- and high-risk women, but 
little is known about these patterns for anal cytology among MSM. 
 
Methods: We analyzed Multicenter AIDS Cohort Study (MACS) data for MSM who were offered 
anal cytology testing annually (HIV-positive, n=708) or every 2 years (HIV-negative, n=796) for 4 
years. After excluding men with anal dysplasia treatment during testing, at least 2 valid anal cytology 
results were available for 474 HIV-negative and 502 HIV-positive MSM, and at least 3 valid results 
for 328 HIV-positive MSM. Inverse probability weighting was used to address possible selection bias. 
 
Results: Following an initial negative (normal) cytology, the frequency of a second negative cytology 
was lower among HIV-positive MSM with CD4≥500 (74%) or CD4<500 (68%) than HIV-negative 
MSM (83%) (p<0.001). After an initial abnormal cytology, the frequency of a second abnormal 
cytology was highest among HIV-positive MSM with CD4<500 (70%) compared to CD4≥500 
(53%) or HIV-negative MSM (46%) (p=0.003). Among HIV-positive MSM with at least three results, 
37% had 3 consecutive negative results; 3 consecutive abnormal results were more frequent among 
CD4<500 (22%) than CD4≥500 (10%) (p=0.008).  
 
Conclusions: More than one-third of HIV-positive MSM have consistently negative anal cytology 
over three years. Following abnormal anal cytology, a repeated cytology is commonly negative in 
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HIV-negative or immunocompetent HIV-positive men, while persistent cytological abnormality is 
more likely among HIV-positive men with CD4<500. 
 
3.2  Introduction 
Anal cancer is rare in the United States general population (1.8 per 100,000),45,46 though rates 
are increasing.47 In contrast, incidence among HIV-seropositive men who have sex with men (HIV-
positive MSM) is extremely high, estimated at 131 per 100,000,48 due to increased human 
papillomavirus (HPV) prevalence and HIV-associated immunosuppression.51 During 2001-2005, 
approximately 28% of U.S. anal cancers in males occurred in men living with HIV, the vast majority 
in HIV-positive MSM.106 This burden is likely growing as the HIV-positive population size 
increases,5,7 though the trend in anal cancer incidence is unclear.4,107 Anal cancer is also a concern for 
HIV-negative MSM, who have incidence 30-fold higher than the general population.49,108 
There is an urgent need for effective anal cancer screening methods among MSM. Though no 
national or international guidelines exist,50 the primary strategy is screening by anal cytology 
(collected with an anal swab) with referral to high-resolution anoscopy (HRA) for possible biopsy, 
diagnosis, and treatment of anal precancer/cancer.32,51,52 This approach is analogous to cervical 
cancer screening by cytology with referral to colposcopy, but is not as well described.51,53,54 Using a 
threshold of ASC-US (atypical squamous cells of undetermined significance) and higher grades of 
cellular dysplasia on cytology as a positive screen, the sensitivity of both anal and cervical cytology 
for biopsy-confirmed high-grade dysplasia are estimated at 90%; however, specificity appears lower 
for anal vs. cervical cytology (33% vs. 53%).109  
Due to the challenges and uncertainty associated with anal cytology, some have proposed that 
HIV-positive MSM be referred directly to HRA.55 However, while anal cytology has high 
acceptability among MSM,56,57 there are a limited number of trained and experienced HRA providers, 
a higher cost for the procedure, and uncertain benefits of screening using this diagnostic tool. Thus, 
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evaluating whether using cytology may be appropriate to identify men who do or do not need HRA 
is an important goal.  
At the cervix, the predictive value of repeated cytology results (e.g., 3 consecutive negative 
results) is frequently utilized in screening guidelines.40,63 For anal cytology, however, it is not known 
what proportion of HIV-positive MSM have consistently negative results. Further, different 
transition probabilities, such as the likelihood of a negative cytology if the previous cytology was 
abnormal, have not been described for anal cytology nor compared by HIV or immune status. Such 
data could inform decisions regarding when and whether to repeat anal cytology or refer MSM to 
HRA. 
 
3.3  Methods 
Study Population 
 We analyzed data from the Multicenter AIDS Cohort Study (MACS), a cohort study of HIV-
positive and HIV-negative men who have sex with men (MSM). The MACS has 4 United States sites 
(Baltimore, Chicago, Pittsburgh, and Los Angeles) and has been ongoing since 1984. Visits occur 
every 6 months and include routine collection of biological and behavioral covariates of interest. For 
this sub-study, all MACS participants who attended any study visits between June 2010 and July 2011 
were offered a free anal cytology test, with collection and testing done as previously described.54 Men 
with unsatisfactory cytology results were offered another test at their next visit. By design, over the 
study period, HIV-positive men were offered annual cytology (up to 4 cytologies total), whereas 
HIV-negative men were offered a second cytology 2 years later (2 cytologies total). Thus, our 
analyses including both HIV-positive and HIV-negative MSM describe 2 cytology results typically 
collected 1 and 2 years apart, respectively. Analyses examining 3 or more cytology results could be 
performed among HIV-positive MSM only. Information about HRA and treatment of anal dysplasia 
occurring outside of regular MACS visits was collected using participant questionnaires and 
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subsequent medical record review. This MACS sub-study was approved by the institutional review 
boards of each participating site. 
Statistical Analysis 
A substantial proportion (18%) of cytology results were classified as being unsatisfactory for 
evaluation. For the purposes of this analysis (excluding the generation of inverse probability weights 
described below) we omitted these results and only considered results deemed sufficient for 
interpretation. Adequate (valid) specimens were classified as negative (normal) or abnormal: ASC-US, 
low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells cannot exclude HSIL 
(ASC-H), or high-grade squamous intraepithelial lesion (HSIL). As we stratify by HIV status, we 
excluded 1 man who acquired HIV after his first cytology. Men who had treatment of anal dysplasia 
(including imiquimod cream, trichloroacetic acid, cryotherapy, electrocautery, infrared coagulation, or 
surgery) between their first and second cytology (N=38) were excluded from all analyses. For 
analyses considering 3 consecutive cytologies (HIV-positive MSM only), 14 additional men with 
treatment between the second and third cytology were excluded. 
Among men with at least 2 valid cytology tests, and considering only the first 2 valid 
(consecutive) results, we calculated frequencies of having a negative (vs. abnormal) cytology 
following a negative or abnormal cytology. We compared these frequencies across HIV-negative 
MSM and HIV-positive MSM with absolute CD4+ T cell counts (CD4) ≥500 cells/μL 
(immunocompetent) and <500 cells/μL (potentially immunocompromised) at the first cytology; p-
values were calculated using chi-square tests across all three groups. We also present this analysis 
after dividing abnormal results into more detailed categories. Among HIV-positive MSM with at least 
3 valid results, we also calculated frequencies of having a negative (vs. abnormal) cytology at the third 
consecutive anal cytology following 2 consecutive negative or 2 consecutive abnormal cytologies, and 
compared these frequencies by CD4 count at the first cytology; p-values were calculated using chi-
square tests across the two HIV-positive groups. 
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We recognized potential for selection bias in our analysis set of HIV-positive MSM with at 
least 3 valid results and no anal dysplasia treatment (N=328), as this group represented less than half 
of the HIV-positive MSM who originally had at least one anal swab for cytology collected (N=708). 
Therefore, we applied inverse probability weights in the analyses of cytology patterns conducted 
among this group. We generated the weights using a logistic regression model including variables 
potentially related to consistent participation in cytology testing, including study center, wave of 
enrollment into cohort, age, race/ethnicity, educational level, first cytology result (including 
inadequate), HAART status, and number of sexual partners. Weights were stabilized by dividing the 
overall proportion with complete data by each individual’s model-predicted probability of having 
complete data. We then applied these stabilized weights when calculating the prevalence of cytology 
patterns among HIV-positive MSM, and when fitting a logistic model comparing characteristics of 
men with consistently abnormal vs. consistently negative cytology (described below). 
Among HIV-positive MSM with at least 3 valid cytologies, we classified men as having 
different patterns of negative and abnormal results (e.g., negative-abnormal-negative) by considering 
the first 3 valid results. As a descriptive analysis, we further restricted to HIV-positive MSM with 
either consistently abnormal results (i.e., 3 consecutive abnormal cytologies) or consistently negative 
results (i.e., 3 consecutive negative cytologies) and fit a logistic regression model to compare 
demographic, behavioral, and biological characteristics between these two groups. 
 
3.4  Results 
 A total of 796 HIV-negative and 708 HIV-positive MSM had at least one anal swab collected 
and evaluated for anal cytology, including inadequate results (Table 3.1, top portion). Since the focus 
of this analysis was on patterns in repeated anal cytology, all analyses were restricted to MSM with at 
least two valid cytology results (Table 3.1, bottom portion). Among the HIV-negative MSM, who 
typically only had 2 opportunities to have anal cytology collected, 474/796 (60%) had 2 valid results 
after excluding 6 men with anal dysplasia treatment between their first and second cytology; the 
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median time interval between valid cytologies for HIV-negative MSM was 2.0 years (IQR 1.9-2.2). 
Among the HIV-positive MSM, who had up to 4 anal cytologies collected, 502/708 (71%) had at 
least 2 valid results after excluding 32 men with anal dysplasia treatment; the median time interval 
between valid cytologies was 1.0 years (IQR 0.96-1.3). Among these MSM, the median age was 58 
years for HIV-negative and 54 years for HIV-positive MSM. Consistent with the MACS participants 
overall, most men in this sub-study were non-Hispanic White and had at least a college education. 
Among HIV-positive MSM, the median current CD4 cell count (at the first cytology) was 579 
cells/μL, while the median nadir CD4 count (prior to first cytology) was 252 cells/μL. When 
summarizing all MACS visits over the last 5 years, the mean number of condomless receptive anal 
sex partners reported at each visit was 1.0 or more for 12% of HIV-negative and 27% of HIV-
positive men. 
 We compared the frequency of a negative (vs. abnormal) cytology following an initial 
negative or abnormal cytology by HIV and CD4 status at the first cytology (Table 3.2). After an 
initial negative cytology, the frequency of a negative result on the second cytology (without 
accounting for differences in time interval) was 83%, 74%, and 68% among HIV-negative MSM, 
HIV-positive MSM with CD4≥500, and HIV-positive MSM with CD4<500, respectively (p<0.001). 
After an initial abnormal cytology, corresponding frequencies of an abnormal result on the second 
cytology (without accounting for differences in time interval) were 46%, 53%, and 70% (p=0.003).  
When the analyses were restricted to cytologies that were within 18-30 months of each other, so that 
HIV-negative and HIV-positive MSM had similar time intervals between tests (Table 3.3), 
consecutive negative cytologies were still most frequent in HIV-negative MSM (83%), but there was 
no appreciable difference between the HIV-positive groups based on CD4 count (73-74%; overall 
p=0.02). For consecutive abnormal cytologies, as in the primary analysis, the results showed 
comparable frequencies in HIV-negative MSM and HIV-positive MSM with CD4≥500 (43% and 
40%, respectively), and higher frequency in HIV-positive MSM with CD4<500 (65%, overall 
p=0.02).  
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Further stratification of results from the first and second cytologies (Table 3.2) revealed that 
ASC-US results at the second cytology accounted for more than three-quarters of abnormal results 
following an initial negative cytology, with LSIL or higher grade results occurring in 6% of men or 
less, regardless of HIV or CD4 status. After an initial ASC-US cytology, more than one-quarter of 
men (27-31%) had ASC-US at their second cytology in all groups, while LSIL was more common in 
HIV-positive MSM with CD4<500 (27%) than CD4≥500 (14%) or HIV-negative MSM (6%) 
(overall p=0.07). ASC-H and HSIL results were generally uncommon, but did represent 6-10% of 
results following an initial cytology of LSIL or higher grade. 
Among HIV-positive MSM only, we also compared the frequency of a negative or abnormal 
cytology following 2 consecutive negative or abnormal cytologies (Table 3.2). After 2 consecutive 
negative cytologies, the frequency of the third cytology remaining negative was high (74-77%) 
regardless of CD4 count (p=0.84). However, after 2 consecutive abnormal cytologies, the frequency 
of the third cytology remaining abnormal was higher among HIV-positive MSM with CD4<500 
(79%) compared to CD4≥500 (60%), though the difference did not quite reach statistical significance 
(p=0.08).  
  Among the 708 HIV-positive MSM who had at least one cytology collected, 328 (46%) had 
at least 3 valid results and no treatment.  Among these 328 HIV-positive MSM, we explored 
frequencies of different patterns of results observed over the first 3 cytologies, using inverse-
probability weighting to approximate what would have been observed in the original 708 MSM 
(Table 3.4). Across categories of CD4 count, 37-38% of HIV-positive MSM had consistently (3 out 
of 3) negative cytology; thus, a high proportion (62-63%) had abnormal results for at least 1 of the 3 
cytologies. However, most men did not have consistently abnormal cytology, and the proportion of 
men with consistently abnormal cytology was higher among HIV-positive MSM with CD4<500 than 
CD4≥500 (22% vs. 10%, p=0.008). Conversely, the proportion of men with 2 negative and 1 
abnormal cytology was lower among HIV-positive MSM with CD4<500 vs. CD4≥500 (25% vs. 
35%). A pattern of 1 negative and 2 abnormal cytologies was also common in both groups (16-17%). 
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A detailed description of all patterns across the first 3 consecutive cytologies in HIV-positive MSM is 
provided in Table 3.5. 
 Finally, we explored demographic, behavioral, and biological risk factors for a consistently 
(over 3 consecutive results) abnormal cytology pattern, compared to a consistently negative pattern, 
using inverse-probability weighted logistic regression (Table 3.6). The odds of consistently abnormal 
cytology increased by 28% with each 100 cells/μL decrease in CD4 cell count at the first cytology 
(95%CI 4-59%). Additionally, a nadir CD4 cell count less than 100 cells/μL (threshold chosen based 
on exploratory analysis) indicated 4.4-fold higher odds of consistently abnormal cytology (95%CI 
1.2-16.5). Men who reported a mean of 1 or more condomless receptive anal sex partners at each 
visit over the past 5 years had 5.7-fold higher odds (95%CI 2.1-15.2) compared to men who reported 
fewer or none of these partners. Odds of consistently abnormal cytology were increased in men aged 
60 and older (OR 6.1, 95%CI 1.3-27.6) and of non-white race/ethnicity (OR 6.2, 95%CI 1.9-20.0).  
 
3.5  Discussion 
 Using anal cytology to assist in identifying MSM who might (or might not) have risk for anal 
dysplasia is an important goal. This is particularly true for HIV-positive MSM, who are at high risk of 
anal cancer. In one of few studies to repeatedly collect and evaluate anal swabs for cytological 
abnormalities, our data show that more than one-third of our population of HIV-positive MSM have 
consistently negative (normal) anal cytology when tested three times over the course of 
approximately three years. Since negative anal cytology may indicate lower risk of ultimate 
development of anal cancer, it is possible that repeatedly negative cytology might define a subset of 
HIV-positive MSM who are at lower anal cancer risk and thus less likely to benefit from an invasive 
procedure such as HRA. Conversely, consistently abnormal anal cytology in HIV-positive MSM over 
a three-year period may identify men at higher risk of anal dysplasia. A fluctuating pattern of negative 
and abnormal cytology was very common, but additional research is necessary to understand how 
such a pattern should be interpreted. 
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Even among MSM with the same recent cytology result, we found that the likelihood of the 
next cytology being abnormal was related to HIV status or to the level of HIV-associated 
immunosuppression. After a negative cytology result, a second negative cytology was seen in the 
majority of men regardless of HIV or CD4 status, but the frequency was lower in HIV-positive 
MSM. When the first cytology was abnormal, the likelihood that the next result would remain 
abnormal was highest among HIV-positive MSM with CD4<500 cells/μL, with much lower 
frequencies of a second abnormal Pap in HIV-positive MSM with CD4>500 cells/μL and HIV-
negative MSM. One of multiple possible explanations for this finding is that anal dysplasia was less 
likely to regress in more immunosuppressed men, but this topic is poorly studied.110,111 Some data do 
suggest that HIV reduces clearance of anal HPV.58,112,113 
Our findings motivate further study of the utility of repeated cytology for managing an initial 
abnormal cytology. For example, MSM with an initial ASC-US cytology (the least severe of the 
abnormal cytology results) were likely to have a negative second cytology if HIV-negative (60%) or 
HIV-positive with CD4>500 cells/μL (58%). If this accurately represents a low-risk status (which we 
did not investigate here), then repeating cytology after an ASC-US result may provide one way to 
distinguish between men who are not at high risk of anal dysplasia and men who might benefit from 
prompt referral to HRA. Repeated cytology was less likely to revert to negative among HIV-positive 
MSM with lower CD4 counts, particularly when the initial result was LSIL or worse. 
 Compared to HIV-positive MSM with 3 consecutive negative anal cytologies, we found that 
HIV-positive MSM with 3 consecutive abnormal cytologies were more likely to be older, of 
race/ethnicity other than non-Hispanic white, to have lower CD4 counts at first cytology as well as 
lower nadir CD4 counts, and to have more condomless receptive anal sex partners. These 
characteristics are largely consistent with known risk factors for having anal lesions/cancer or for 
acquiring anal HPV.108,114–116 One possible explanation for the higher likelihood of persistently 
abnormal cytology among non-white HIV-positive MSM is that, in our data, the likelihood of 
treatment for anal dysplasia after a first abnormal cytology was 30% among white non-Hispanic men 
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compared to only 12% among other men (p=0.002). Thus, white non-Hispanic men with a first 
abnormal cytology were more likely to be excluded from the cytology-patterns analysis, and the racial 
difference that we observed might be due to other factors related to treatment access or treatment-
seeking behavior. We recommend further study of this difference in the likelihood of referral and 
potential treatment, as an analogous disparity in follow-up after abnormal cervical cytology has 
produced a substantial racial disparity in cervical cancer incidence among older U.S. women.117 
 Our results show that using repeated anal cytology over time identifies patterns of negative 
and abnormal anal cytology. These patterns may have potential to identify men at low and high risk 
of anal lesions. We emphasize that anal cytology screening is not diagnostic, and cannot prevent anal 
cancer without the possibility of referral to HRA among those identified to be at risk. Digital 
anorectal examination should always be included in the evaluation of individuals at risk for anal 
dysplasia, and can be used to identify some anal cancers at earlier stages if HRA is not readily 
available.118,119 Importantly, our analyses did not relate anal cytology patterns (from anal swabs) to 
histologically verified anal dysplasia (from anal biopsies). The utility of repeated anal cytology can 
only be confirmed through unbiased follow-up by HRA (i.e., HRA in MSM with both negative and 
abnormal anal cytology results) and biopsy when indicated.  
It is not yet clear whether, as in cervical cancer screening, molecular testing of anal swabs for 
the presence of oncogenic HPV subtypes, or co-testing for HPV subtype and cytology, will help 
overcome the current suboptimal diagnostic accuracy of anal cytology testing alone.120 The 
prevalence of anal HPV is very high among HIV-positive MSM, though testing specifically for 
HPV16 (which confers higher risk) may have utility in screening, including for triage of lower-risk 
abnormal cytology results.58,121 
 Our analysis did not directly relate cytology patterns to histologically verified anal precancer, 
and thus we cannot say (for example) that risk of biopsy-confirmed anal HSIL is truly lower among 
those with consistently negative cytology. While this is likely to be true, it must be studied directly. In 
addition, treatment of anal HSIL has not yet been conclusively shown to prevent anal cancer; this is 
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the topic of an ongoing randomized trial.59 We did not have complete data on serial anal cytology for 
all participants, but we attempted to correct for potential selection bias using inverse probability 
weighting. We also did not attempt to describe or account for differences in demographic, biological, 
or behavioral characteristics by HIV status or CD4 count when calculating the prevalence of 
different transition probabilities and cytology patterns. Such differences, such as higher numbers of 
condomless receptive anal sex partners among HIV-positive MSM, could contribute to some of the 
differences in cytology patterns across groups. Finally, while the MACS study is a large and rich data 
source for studying HIV among MSM, it may not be representative of all HIV-positive MSM in the 
U.S.122 Despite these limitations, we hope that our comprehensive description of anal cytology 
patterns by HIV and CD4 status may inform management of anal cytology results and suggest new 
avenues for future research. 
 In conclusion, for HIV-negative and HIV-positive MSM, patterns of repeated anal cytology 
may prove useful as an indicator of low or high risk of anal disease. More than one-third of HIV-
positive MSM have consistently negative annual anal cytology over 3 years, and lower CD4 counts 
are associated with consistently abnormal anal cytology and with a transition to abnormal cytology 
after a negative cytology. Further study of the cytology patterns we described, including direct 
relation of cytology patterns to biopsy-confirmed anal precancer, will be important to enable more 
effective anal cancer prevention for MSM. 
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3.7  Tables and Figures 
 
Table 3.1 Description of HIV-negative and HIV-positive men who have sex with men (MSM) in the MACS study 
with anal cytology testing 
Number of anal cytology tests 
HIV-negative MSM HIV-positive MSM 
N with valid results (N with any results) 
    1 or more 752 (796) 665 (708) 
    2 or more 480 (625) 534 (593) 
    3 or more NA 369 (484) 
   
Characteristics of MSM included in analyses (2 or more 
valid anal cytologies, no anal dysplasia treatment) 
HIV-negative MSM HIV-positive MSM 
N (%) or median (IQR) 
Total number MSM 474 502 
Age, years (at first cytology) 58 (51-64) 54 (50-59) 
Race/ethnicity   
    Non-Hispanic white 410 (86) 325 (65) 
    Non-Hispanic black 39 (8) 129 (26) 
    Hispanic 19 (4) 40 (8) 
    Other 6 (1) 8 (2) 
Education   
    12th grade or less 95 (20) 194 (39) 
    College graduate 158 (33) 173 (34) 
    Post-graduate 173 (36) 107 (21) 
    Unknown 48 (10) 28 (6) 
Study site   
    Baltimore 130 (27) 131 (26) 
    Chicago 37 (8) 150 (30) 
    Pittsburgh 149 (31) 102 (20) 
    Los Angeles 158 (33) 119 (24) 
CD4 count at first cytology, cells/μL NA 579 (429-749) 
Nadir CD4 count (as of first cytology), cells/μL NA 252 (154-354) 
Currently on HAART (at first cytology) NA 433 (88) 
Time since first HAART (at first cytology), years NA 11.8 (7.4-13.8) 
Mean number of condomless receptive anal sex partners 
reported at each visit during the previous 5 years 
  
    0 307 (65) 254 (52) 
    0.1-0.9 107 (23) 103 (21) 
    1.0 or more 58 (12) 135 (27) 
 
MSM, men who have sex with men; HAART, highly active antiretroviral therapy; MACS, Multicenter AIDS Cohort Study. 
Small numbers of missing values are excluded and percentages may not sum exactly to 100 due to rounding. Men with 
treatment of anal dysplasia between the 1st and 2nd cytology (N=38) are excluded in the lower portion of the table. For 
analyses involving 3 cytology results, HIV-positive men with treatment between the 2nd and 3rd cytology (N=14) were 
additionally excluded. 
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Table 3.2 Frequencies of the next anal cytology result following 1 or 2 initial cytologies that were negative or 









After 1 negative cytology 355 206 114 <0.001 
    Negative cytology 295 (83) 153 (74) 77 (68)  
    Abnormal cytology 60 (17) 53 (26) 37 (33)  
After 1 abnormal cytology 119 99 81 0.003 
    Negative cytology 64 (54) 47 (48) 24 (30)  
    Abnormal cytology 55 (46) 52 (53) 57 (70)  
After 1 negative cytology 355 206 114 0.005 
    Negative cytology 295 (83) 153 (74) 77 (68)  
    ASC-US cytology 46 (13) 44 (21) 30 (26)  
    LSIL/ASC-H/HSIL cytology 14 (4) 9 (4) 7 (6)  
After 1 ASC-US cytology 85 59 41 0.07 
    Negative cytology 51 (60) 34 (58) 17 (41)  
    ASC-US cytology 26 (31) 16 (27) 12 (29)  
    LSIL cytology 5 (6) 8 (14) 11 (27)  
    ASC-H/HSIL cytology 3 (4) 1 (2) 1 (2)  
After 1 LSIL/ASC-H/HSIL cytology 34 40 40 0.49 
    Negative cytology 13 (38) 13 (33) 7 (18)  
    ASC-US cytology 11 (32) 12 (30) 14 (35)  
    LSIL cytology 8 (24) 11 (28) 16 (40)  
    ASC-H/HSIL cytology 2 (6) 4 (10) 3 (8)  
After 2 negative cytologies -- 102 51 0.84 
    Negative cytology -- 75 (74) 39 (77)  
    Abnormal cytology -- 27 (27) 12 (24)  
After 2 abnormal cytologies -- 35 38 0.08 
    Negative cytology -- 14 (40) 8 (21)  
    Abnormal cytology -- 21 (60) 30 (79)  
 
N or N (%). MSM, men who have sex with men; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-
grade squamous intraepithelial lesion; ASC-H, atypical squamous cells cannot exclude HSIL; HSIL, high-grade squamous 
intraepithelial lesion. Men with treatment of anal dysplasia during the cytologies being considered were excluded for each 
analysis (see Methods), as were 2 HIV-positive men with missing CD4 cell counts. Data are unweighted and p-values were 
calculated using chi-square tests. Due to differences in study design, the median length of time between cytologies was 
longer for HIV-negative MSM (2.0 [IQR 1.9-2.2] than for HIV-positive MSM (1.0 years [IQR 0.96-1.3]). Percentages may 
not sum exactly to 100 due to rounding. 
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Table 3.3 Frequencies of the next anal cytology result following an initial negative or abnormal cytology result 








After 1 negative cytology 279 140 69 0.02 
    Negative cytology 233 (83) 102 (73) 51 (74)  
    Abnormal cytology 46 (17) 38 (27) 18 (26)  
After 1 abnormal cytology 93 55 51 0.02 
    Negative cytology 53 (57) 33 (60) 18 (35)  
    Abnormal cytology 40 (43) 22 (40) 33 (65)  
 
N or N (%). MSM, men who have sex with men. Men with treatment of anal dysplasia during the cytologies being 
considered were excluded for each analysis. Data are unweighted and p-values were calculated using chi-square tests. This 
analysis was performed to assess the impact of differential intervals between cytologies for HIV-negative vs. HIV-positive 
MSM; in this table, data are restricted to cytology results spaced by 18-30 months. Results can be compared to Table 2, 
where intervals between cytologies tended to be longer for HIV-negative MSM than for HIV-positive MSM. Percentages 
may not sum exactly to 100 due to rounding. 
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Table 3.4 Patterns of the first 3 consecutive anal cytology results among 328 HIV-positive MSM with at least 3 






Consistently negative 37% 38% 
    Negative – Negative – Negative    37%    38% 
2 negative, 1 abnormal 35% 25% 
   Negative – Negative – Abnormal    11%    7% 
   Negative – Abnormal – Negative    9%    8% 
   Abnormal – Negative – Negative    15%    9% 
1 negative, 2 abnormal 17% 16% 
   Abnormal – Abnormal – Negative    8%    5% 
   Abnormal – Negative – Abnormal    4%    4% 
   Negative – Abnormal – Abnormal    7%    7% 
Consistently abnormal 10% 22% 
   Abnormal – Abnormal – Abnormal    10%    22% 
 
MSM, men who have sex with men. Percentages are weighted to correct for missing cytology-pattern data among 708 
eligible HIV-positive MSM (i.e., 708 HIV-positive MSM with at least one anal cytology specimen collected). Men with 
treatment for anal dysplasia between the first and third cytology were excluded, as were 2 men with missing CD4 cell 
counts. Numbers may not sum exactly to 100 due to rounding. 
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Table 3.5 Prevalence of detailed anal cytology patterns among 328 HIV-positive men who have sex with men 
(MSM) with at least 3 valid cytologies 
Pattern Percent  Pattern Percent 
Negative – negative – negative  37.4%  ASC-H – negative – ASC-US 0.6% 
Negative – negative – ASC-US 8.0%  ASC-H – negative – LSIL 0.5% 
Negative – negative – LSIL 0.8%  ASC-H – ASC-US – negative 0.2% 
Negative – negative – ASC-H 0.6%  ASC-H – ASC-US – ASC-US 0.3% 
Negative – ASC-US – negative 6.1%  ASC-H – ASC-US – LSIL 0.4% 
Negative – ASC-US – ASC-US 4.3%  ASC-H – ASC-H – LSIL 0.5% 
Negative – ASC-US – LSIL 1.0%  LSIL – negative – negative 1.5% 
Negative – ASC-US – ASC-H 0.3%  LSIL – negative – ASC-US 1.2% 
Negative – ASC-US – HSIL 0.2%  LSIL – ASC-US – negative 0.8% 
Negative – LSIL – negative 2.6%  LSIL – ASC-US – ASC-US 3.3% 
Negative – LSIL – ASC-US 0.2%  LSIL – ASC-US – LSIL 0.9% 
Negative – LSIL – LSIL 0.5%  LSIL – LSIL – negative 1.9% 
Negative – ASC-H – ASC-US 0.2%  LSIL – LSIL – ASC-US 1.8% 
ASC-US – negative – negative 11.0%  LSIL – LSIL – LSIL 1.8% 
ASC-US – negative – ASC-US 1.2%  LSIL – ASC-H – negative 0.3% 
ASC-US – negative – LSIL  0.6%  LSIL – HSIL – LSIL 0.2% 
ASC-US – ASC-US – negative 2.9%  HSIL – ASC-US – ASC-H 0.2% 
ASC-US – ASC-US – ASC-US 1.3%  HSIL – LSIL – ASC-US 0.2% 
ASC-US – ASC-US – LSIL 0.9%  HSIL – HSIL – ASC-US 0.2% 
ASC-US – LSIL – negative 0.5%  HSIL – HSIL – HSIL 0.3% 
ASC-US – LSIL – ASC-US 1.5%    
ASC-US – LSIL – LSIL 0.4%    
ASC-US – ASC-H – negative  0.2%    
ASC-US – HSIL – LSIL 0.2%    
 
Percentages are weighted to correct for missing cytology-pattern data among 708 eligible HIV-positive MSM (i.e., 708 HIV-
positive MSM with at least one anal cytology specimen collected); unweighted results were similar. Men with treatment for 
anal dysplasia between the first and third cytology were excluded. 
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Table 3.6 Logistic regression model identifying risk factors for a pattern of first 3 consecutive abnormal anal 
cytologies (N=51) compared to first 3 consecutive negative cytologies (N=115) among HIV-positive MSM 
Characteristic at first cytology Adjusted odds ratio (95% CI) 
Absolute CD4 cell count, per 100 cells/μL decrease 1.28 (1.04-1.59) 
Nadir CD4 count as of first cytology  
   ≥100 cells/μL Reference 
   <100 cells/μL 4.4 (1.2-16.5) 
Mean number of condomless receptive anal sex partners reported at 
each visit during the previous 5 years 
 
   0-0.9 Reference 
   1.0 or more 5.7 (2.1-15.2) 
Age, years  
   <50 Reference 
   50-59 1.2 (0.32-4.5) 
   ≥60 6.1 (1.3-27.6) 
Race/ethnicity  
   Non-Hispanic white Reference 
   Any other 6.2 (1.9-20.0) 
 
Higher odds ratios indicate a higher likelihood of having 3 consistently abnormal cytologies, as compared with having 3 
consistently negative cytologies. Cytology was tested approximately annually. Odds ratios are weighted to correct for 
missing cytology-pattern data among 708 eligible HIV-positive MSM (i.e., 708 HIV-positive MSM with at least one anal 
cytology specimen collected). Men with treatment for anal dysplasia between the first and third cytology were excluded. 
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Chapter 4: Updating Individual Lung Cancer Risk during CT 
Screening to Identify those who Might Lengthen Screening 
Intervals 
 
4.1  Abstract 
Background: To facilitate individual decisions regarding when to return for screening, individual 
disease risk should be updated after screening tests. We calculated how individual lung cancer risk 
evolved based on CT findings during the National Lung Screening Trial (NLST). 
 
Methods: We developed a simple model for risks of interval and screen-detected (“next-screen”) 
lung cancer among 25,762 NLST CT-group participants, all of whom underwent yearly screening. 
First, each participant’s 1-year lung cancer risk in the absence of screening (“pre-screening risk”) is 
calculated based on their risk factors using a validated model. Then, risks of interval and next-screen 
lung cancer are calculated to be the pre-screening risk raised to a power determined by the results of 
the screen. 
 
Results: Median 1-year pre-screening risk was 0.32% (IQR=0.19%-0.53%). Only the most recent 
screening result, not prior results, affected the risk prediction (p>0.2). Among screen-negatives, 
median interval-cancer risk decreased 6.4-fold to 0.05% (IQR=0.02%-0.09%), but next-screen lung 
cancer detection changed little from pre-screening risk (median=0.29%). However, for the 70% of 
screen-negatives without CT-detected emphysema or consolidation (51% of participants), next-
screen detection was 1.8-fold lower than pre-screening risk (median=0.18%). In contrast, after a 
false-positive screen, median next-screen lung cancer detection increased 4.9-fold to 1.5% 
(IQR=1.1%-2.3%) and varied widely by false-positive nodule features (size, location, growth, and 
margins).  
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Conclusions: Screen-negatives without CT-detected emphysema or consolidation, comprising half 
of NLST participants, maintained reduced lung cancer risk at the next annual screen and thus might 
safely return at longer intervals. In contrast, most false-positives experienced substantially increased 
lung cancer detection at the next screen. 
 
4.2  Introduction 
 The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer 
mortality with 3 rounds of CT screening versus chest radiography.11 The U.S. Preventive Services 
Task Force now recommends annual CT screening for ever-smokers aged 55-80 years who smoked 
at least 30 pack-years and quit no more than 15 years ago.71 However, selecting ever-smokers for 
screening based on individualized pre-screening risk calculations may improve the effectiveness, 
efficiency, and cost-effectiveness of screening,21,72–74 and National Comprehensive Cancer Network 
guidelines now allow this approach.123 Online risk tools124,125 enumerate individualized benefits and 
harms of screening to aid decision-making. 
 Once beginning screening, risk-based decisions could also be made regarding screening 
intervals, triage testing, and exiting from screening. For example, in diabetic retinopathy screening, 
choosing screening frequency based on risk substantially reduced patient burden and costs, yet 
maintained safety against clinically significant disease.126 Considering risk-based screening intervals is 
particularly important for CT lung screening, which has high rates of false-positivity that lead to 
excess complications, harm, and costs. The NLST had 24% screen-positivity, of which 96.4% were 
false-positives.11 A Veterans Health Administration screening demonstration project experienced 
60% screen-positivity, of which 97.5% were false-positives.12 Allowing longer intervals for those at 
lower risk would reduce the number of screens and false-positives, thus enabling individualized cost-
effective screening that maintains safety.   
Risk-based intervals require that individual risk – originally calculated prior to screening – be 
updated as test results accrue. Several validated models predict individual risk of lung cancer in the 
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absence of screening based on demographic, smoking, and health-related risk factors,72,73,127–133 and 
others calculate the current probability of lung cancer when a nodule is identified on CT.134 However, 
for screened individuals believed to be cancer-free (i.e., the screen result was negative or false-
positive), no model provides an updated estimate of future risk based on the current screen result and 
individual risk factors.  
 We developed a simple model that quantifies how individual risk evolved during annual CT 
screening in the NLST. First, individual pre-screening 1-year lung cancer risk is calculated using the 
validated Lung Cancer Risk Assessment Tool (LCRAT).73,124 Then, the model calculates how pre-
screening risk is modified by screen results (negative or false-positive) and CT features such as 
nodule characteristics or CT-diagnosed emphysema. This model encapsulates the effects of a 
negative or false-positive result on future risk, which, along with individual risk factors, determine 
when an individual should return for screening. 
 
4.3  Methods 
Data Source and Definitions 
 The NLST randomized 53,454 ever-smokers to 3 annual screens (denoted T0, T1, and T2) 
with either low-dose CT or radiography.11 Eligibility required age 55-74 years, 30 or more pack-years 
of smoking, and 15 or fewer quit-years. We analyzed lung cancer risk among 25,762 participants 
randomized to CT screening, where a positive screen was defined by at least one non-calcified nodule 
with longest diameter at least 4 mm or other suspicious abnormalities (NLST modified Fleischner 
criteria11,135). Screen-negatives returned for re-screening in 1 year while screen-positives had complex 
follow-up, often involving repeat CTs, at the discretion of providers.11,136 
 We related CT screening results to lung cancer risk over the subsequent 1-year interval and 
at the next annual screen. “Interval cancers” were defined as cases developing within 1 year of a 
negative CT and before the next screen.137 Individuals were at risk for interval cancer during each of 
the three 1-year intervals that followed a negative CT. We defined a screen-detected (i.e., “next-
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screen”) cancer as a case most likely diagnosed because of a positive CT (Supplementary Methods). 
Individuals were at risk for screen-detected cancer at each screen preceded by a negative or false-
positive result (thus, we could not analyze risk at the first [T0] screen), not preceded by diagnosis 
with interval cancer, and with a valid result (so that lung cancer might be detected). 
 We created variables to describe different features noted on CT, specific to person and 
screen. These included the presence, number, diameter, location, margins, attenuation, and growth of 
nodules, as well as non-nodule features such as emphysema, atelectasis, adenopathy, consolidation, 
and fibrosis (detailed list in Table 4.1). These variables combined information across multiple nodules 
as needed to create a summary variable. 
Statistical Analysis 
We developed first-order Markov transition models138 for the binary indicator of lung cancer 
status to estimate individual interval or next-screen lung cancer risk based on pre-screening risk and 
screen results (details in Supplementary Methods). Given risk factors x, the models first calculate 1-
year pre-screening risk, r0(x), using the Lung Cancer Risk Assessment Tool (LCRAT)73, a validated 
model for lung cancer risk in the absence of screening. LCRAT risk-factors include age, education, 
sex, race, smoking intensity/duration/quit-years, body mass index, family history of lung cancer, and 
self-reported emphysema.73 Next, we fit log-binomial regression models that calculate future risk by 
raising pre-screening risk r0(x) to an exponent specific to screen results. For example, following is the 




Thus, after a negative screen, pre-screening risk is raised to power β0, and after a false-positive 
screen, pre-screening risk is raised to power β0+β1. If two people have the same screen result, then 
the person who had higher pre-screening risk will also have higher next-screen risk. Logistic 
regression models yield similar results but have a more complex risk equation. 
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We examined lung cancer risk in 3 separate settings: interval-cancer risk (among screen-
negatives only), next-screen cancer among screen-negatives, and next-screen cancer among false-
positives.  We did not consider risk following true-positive results, as these participants already had 
cancer.  
We tested whether risk calculations depended only on the most recent screen result (and not 
prior results), by comparing exponents at the T2 screen between groups with the same T1 result but 
different T0 results. Differing exponents would imply that prior screen results continue to influence 
risk calculations. In addition, we tested for equality of exponents across the different NLST screens 
and intervals.  
For the 3 settings described above, we examined the effects of specific features noted on 
CT. In each setting, we separately applied backwards-stepwise selection and the lasso (least absolute 
shrinkage and selection operator)139 to identify strongly associated and biologically plausible features 
(from among 50 features) to include in models (Table 4.1 and Table 4.2). We validated each final 
model using 10-fold cross-validation. Separately, for comparison to the final model for false-
positives, we fit a model for next-screen cancer using retrospectively-assigned Lung-RADS 
categories.140,141  
Finally, we conducted a proof-of-principle analysis to examine the utility of our model for 
identifying individuals who might extend screening intervals. Among participants with a negative or 
false-positive result at the final (T2) screen, we predicted 1-year total risk of interval and next-screen 
cancer using the T2 findings. Then, within quintiles of predicted risk, we calculated the observed 
incidence of lung cancer over the 4 years following screening cessation. 
 
4.4  Results 
Model Development 
Following a negative or false-positive screen, exponents were similar for calculating interval-
cancer risk following T0, T1, or T2 (p=0.32) and for calculating screen-detected lung cancer risk at 
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T1 or T2 (p=0.07) (Supplementary Results). Accounting for the most recent screen, prior results did 
not additionally influence risk calculations, either for interval cancers (p=0.97) or screen-detected 
cancers (p=0.47) (Supplementary Results, Figure 4.1). Thus, we fit models combining data across 
intervals and screens, considering only the most recent screen.  
Risk after a Negative or False-positive CT 
Median 1-year pre-screening risk was 0.32%, and individual risks for the middle 50% of 
participants (IQR) ranged from 0.19% to 0.53% (Figure 4.2). Following 56,927 negative screens from 
23,331 unique individuals, cancer was detected in the 1-year interval following 43 (0.08%) screens 
(Table 4.3). Based on our model incorporating pre-screening risk, r0(x), interval-cancer risk following 
a negative screen decreased per the equation r0(x)1.32 (n.b. exponents greater than 1 imply decreased 
risk). Using the T0 screen result and the T0-T1 interval for illustration, median risk decreased 6.7-
fold from 0.32% pre-screening risk to 0.05% interval-cancer risk between T0 and T1 (IQR=0.02%-
0.09%) (Figure 4.2). 
For diagnosis of screen-detected cancer, we analyzed 35,534 negative and 12,994 false-
positive screens from 19,752 and 8,300 unique individuals, respectively (Table 4.3). Cancer was 
detected at the next screen among 0.39% of the negative screens and 1.8% of the false-positive 
screens, with next-screen detection among screen-negatives calculated as r0(x)1.01. In contrast, 
detection among false-positives increased as r(x)0.74. Using the T0 result and the T1 screen for 
illustration, lung cancer detection at T1 following a negative T0 CT approximated pre-screening risk 
(medians 0.29% vs. 0.32%), while detection at T1 following a false-positive at T0 increased 4.9-fold 
from 0.32% pre-screening risk to 1.5% detection (IQR=1.1%-2.3%) (Figure 4.2). 
Risk based on Specific Features found on a Negative or False-positive CT Screen  
Following a negative or false-positive screen, interval and next-screen lung cancer risks 
varied substantially based on specific CT-image features. These models cross-validated well (Table 
4.4), and the false-positive model out-performed one using Lung-RADS categories (Supplementary 
Results, Table 4.5). 
     64 
Following a negative screen, next-screen risk was elevated if the CT identified either 
emphysema (median risk increased from 0.31% to 0.53%) or consolidation (median risk increased 
from 0.31% to 1.6%) (Figure 4.3). Thirty percent of screen-negatives had CT-diagnosed emphysema, 
regardless of their baseline self-reported emphysema status (7% self-reported emphysema), and 0.6% 
had consolidation. Thus, a large majority (70%) of screen-negatives had neither emphysema nor 
consolidation, and for this group, next-screen lung cancer detection was 1.7-fold lower than pre-
screening risk (from 0.31% to 0.18%). 
Also among screen-negatives, median interval-cancer risk increased over pre-screening risk 
(0.31% vs. 0.66%) for the 2% of screen-negatives with consolidation or adenopathy. Further analysis 
suggests that these should have been classified as positive screens (Supplementary Results, Figure 
4.4). 
Following a false-positive screen, specific features of the nodule(s) strongly modified next-
screen risk (Figure 4.5). Median risk varied widely with longest nodule diameter: 0.49% (4-5mm), 
0.80% (6-7mm), 1.9% (8-10mm), 4.1% (11-13mm), and 4.0% (≥14mm) (Table 4.6). Risk was higher 
if any nodule was in the upper lobes (median 1.4%) or had spiculated margins (4.0%), but was lower 
if all nodules had smooth margins (0.71%). Those with a nodule that grew from T0 to T1 had 22-
fold higher risk at T2 (median 7.7%). The number of nodules did not influence risk after accounting 
for these features (p=0.50).  
For individuals, each CT feature contributes to the risk calculation. For example, for the 
19% of false-positives in the lowest-risk category (only 4-5mm smooth-margins nodules with no 
growth and not in upper lobes), next-screen risk nearly equaled pre-screening risk (r0(x)0.99).  Thus, 
the lowest-risk false-positives have similar next-screen risk as screen-negatives. 
Lung cancer Incidence after Cessation of Screening: Potential for Extending Screening Intervals 
 Among 23,881 participants with a negative or false-positive T2 result, 1-year risk predicted 
by our model ranged from 0.05% at the first percentile to 9.5% at the 99th percentile. Among the 
4,777 participants in the lowest-risk quintile, observed lung cancer incidence during the 4 years 
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following T2 was only 0.08%. Incidence increased in each quintile, reaching 37-fold higher incidence 
(3.1%) among the highest-risk participants (Table 4.7). 
 
4.5  Discussion 
Although many models calculate individual lung cancer risk in the absence of screening, risk-
based decisions during screening require that risk be updated as test results accrue. To identify 
individuals who might safely lengthen their screening interval, we developed a simple model that 
quantifies how individual lung cancer risk evolved during annual CT screening in the NLST. Risk 
calculations depended only on pre-screening risk and the most recent screen result; prior results did 
not further influence risk. Following a negative screen, risk was very low during the next year, but 
lung cancer detection at the next screen nearly equaled pre-screening risk. However, screen-negatives 
without emphysema or consolidation maintained reduced risk at the next screen, suggesting that 
some of them could safely return at a longer interval. Since these participants comprised 51% of the 
NLST, major reductions may be possible in the patient burden and financial costs associated with CT 
lung screening. In contrast, next-screen lung cancer detection was increased for a large majority of 
false-positives, for whom screening intervals should not be extended. 
As expected, a negative screen indicated extremely low risk of lung cancer over the following 
1-year interval. When screen-negatives returned for their next screen, they comprised 2 distinct 
groups: the 30% with CT-detected emphysema or consolidation had higher next-screen detection 
than pre-screening risk, while the 70% without such findings (51% of all participants) maintained 
lower next-screen detection. The subset of these without strong risk factors are potential candidates 
for waiting longer than 1 year to return to screening. Over 4 years following cessation of NLST 
screening, participants with the lowest predicted risks had very low lung cancer incidence, suggesting 
that extended intervals might be safe in practice. 
Surprisingly, a recent false-positive screen indicated substantially higher next-screen lung 
cancer detection. Possible explanations include incorrect determination of false-positivity from 
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images or biopsies, or that a nodule, even if not cancer, may indicate a “field effect” of underlying 
malignant processes that presage incipient cancer elsewhere in the lung.  Importantly, nodule features 
identified on a false-positive CT accounted for elevated risk, and some of these also predict nodule 
malignancy at the current screen (i.e., for true-positive screens).134 There is heterogeneity among false-
positives: individuals with strong risk factors and dangerous CT features have high next-screen lung 
cancer detection, while the 19% of false-positives with only low-risk CT features (no growth, smooth 
margins, small nodules not in upper lobes) have next-screen detection similar to that following a 
negative screen. Further research should explore what follow-up testing is appropriate in very high-
risk individuals, and whether some low-risk false-positives could consider longer screening intervals.  
We found that the most recent screen result sufficed to calculate risk, and that including prior 
screens did not significantly change risk calculations. This is not inconsistent with findings by Patz et 
al. that lung cancer incidence successively decreased with multiple negative screens.75 Patz et al. 
examined whether, given a prior negative screen (e.g. T0), the most recent screen modified risk (e.g. 
T1), whereas we considered the opposite: whether, given the recent screen result (e.g. T1), prior 
results (e.g. T0) further affect risk. Although our findings suggest prior screen results are 
uninformative, there may be small reassurance from sequential negative screens, or small differences 
in detection across different NLST screens (Supplementary Results). Further study of these issues 
requires data describing more than 3 annual screens. 
Our study has limitations. We could not calculate risk under longer screening intervals because 
the NLST had only annual screening. External validation of our model in other annual screening 
settings is crucial. We used our validated LCRAT model to predict 1-year pre-screening risk and did 
not investigate whether other models can be substituted. For simplicity, we also did not “update” 
pre-screening risk if individuals quit smoking or as age, pack-years, and quit-years accumulated. 
Updating risk factors would have negligible effect over 3 screens, but could be done periodically in 
practice. We did not consider specific CT features (e.g. nodule size) in evaluating the potential utility 
of prior screens for risk prediction. 
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Existing risk tools, such as shouldiscreen.com125 and the Risk-based NLST Outcomes Tool,124 
only assist in shared decision-making for entering screening. Our model allows risk to be continually 
updated during screening, requiring that participants be provided counseling and support as risks 
fluctuate. To illustrate how individual lung cancer risk can vary over time, consider a man with the 
median 1-year pre-screening risk (0.32%). If his first CT identifies an 8-mm false-positive nodule in 
the upper lobes with smooth margins, then his next-screen risk increases to (0.32%)(0.73-
0.10+0.07)=1.8%. If at the next screen, his result is negative with no emphysema or consolidation, his 
interval-cancer risk is 0.32%1.32=0.05%, and his next-screen risk is 0.32%1.07=0.21%. Thus, his 1-year 
next-screen risk will be lower than his pre-screening risk (0.21% vs. 0.32%), even though it had once 
been 8.5-fold higher (1.8%). 
Our findings illustrate that even within the CT-screening context, traditional risk factors such as 
smoking history maintain a strong influence on lung cancer risk. More research is needed to 
understand the harms and benefits associated with extending screening intervals in low-risk 
individuals, and to develop shared decision-making processes that allow patients to understand these 
in the context of their individual risks. Our model’s risk calculations take one step toward enabling 
truly risk-based personalized medicine throughout the course of screening: from entry to screening 
intervals, triage testing, and eventual exit from lifetime screening. 
 
4.6  Supplementary Methods 
 
Definition of Screen-detected (“Next-screen”) Lung Cancer 
 Data collected in the NLST do not allow direct identification of lung cancers as “screen-
detected.” Our definition of a screen-detected cancer at T1 or T2 required the following: a positive 
screen and a lung cancer diagnosis before the next screen that occurred either a) within 12 months of 
the positive screen or b) after a continuous sequence of diagnostic procedures that was not broken 
by a gap of greater than 12 months between the screen date and diagnosis date. To consider all 
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relevant cancers, we also included 3 cases that arose more than 1 year after the most recent screen 
and within the window for the subsequent screen but before the screen took place. 
Detailed Description of Modeling Approach 
 A priori, we considered that risk within a screening program is likely to be related to risk in 
the absence of screening. Indeed, in preliminary models, we found that accounting for pre-screening 
risk resulted in strong improvement over a model including screen result only (AIC 4013 vs. 4163). 
We built on our previous work in which we developed and validated a risk model for incident lung 
cancer in the absence of screening called the Lung Cancer Risk Assessment Tool (LCRAT).73 The 
LCRAT was fit to data on 39,180 ever-smokers in the PLCO community care arm, and we have 
validated it in 4 cohorts to ensure it is well-calibrated and has good discrimination: the PLCO chest 
radiography arm,73 NLST chest radiography arm,73 NIH-AARP (under review), and the ACS CPS-II 
(under review). LCRAT is available in our R package lcrisks that also calculates risks from our Lung 
Cancer Death Risk Assessment Tool (LCDRAT) (http://dceg.cancer.gov/tools/risk-
assessment/lcrisks). LCRAT and LCDRAT are also available as part of our R package lcmodels which 
calculates risks from 9 prominent lung cancer risk models (http://dceg.cancer.gov/tools/risk-
assessment/lcmodels). We used LCRAT to predict, for each individual in the NLST CT arm, 1-year 
pre-screening lung cancer risk at baseline. 
Since follow-up and compliance in the NLST CT arm was very complete, our analysis 
considers risk within 1-year intervals only. We began by fitting logistic regression models separately 
for interval and screen-detected cancers, and separately for each screen. As such, these initially 
included (1) 3 models for interval-cancer risk in the 1-year periods following T0, T1, and T2 screens 
and (2) 2 models for screen-detected cancers (risk at T1 as a function of the T0 screen result, and risk 
at T2 as a function of the T1 screen result). Later, upon observing that coefficients were similar 
across screens (see below Supplementary Results), we combined these models to obtain one overall 
model for interval cancers and one for screen-detected cancers.  
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We considered multiple approaches for model parameterization. We used log and logit 
transformations for 1-year pre-screening risk, which gave better fit by likelihood-ratio statistics than 
modeling untransformed risk (data not shown). Initial models included separate terms for 
transformed pre-screening risk and screen result, but we subsequently found and included 
interactions (i.e., products) between these terms. Finally, we removed intercept terms and the main 
effect for screen result, as they did not improve fit and could not be straightforwardly interpreted. 
Throughout analysis, we used logistic regression for model development, as log-binomial models 
frequently encounter challenges with convergence. We changed final models to log-binomial with a 
log transformation of pre-screening risk. This had a negligible effect on model fit but has advantages 
for interpretation, as it allows model coefficients to act as simple exponents of pre-screening risk as 
described below. 
This final approach produced models of the following general form: 
log 𝑟 = 𝛽1 log 𝑟0(𝑥) + 𝑠𝛽2 log 𝑟0(𝑥) 
where: 
𝑟            = predicted risk of interval or screen-detected lung cancer 
𝑟0(𝑥)    = individual 1-year pre-screening risk (calculated using LCRAT73) 
𝑠    = result from most recent screen (e.g. 0=negative, 1=false-positive) 




For example, in the model for risk of next-screen lung cancer based on overall screening result, 𝑠 =
0 for a recent negative result and 𝑠 = 1 for a recent false-positive result. Thus, 𝛽0 is the exponent for 
an individual with a recent negative result, and 𝛽0 + 𝛽1 is the exponent for an individual with a 
recent false-positive result.  
Subsequent models including features noted on CT were formulated analogously, such that 
coefficients are added together to obtain exponents for pre-screening risk. For example, the final 
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model for next-screen lung cancer detection following a false-positive screen based on CT features 




𝑟            = predicted risk of screen-detected lung cancer 
𝑟0(𝑥)    = individual 1-year pre-screening risk 
𝑑0    = no nodule present 
𝑑1    = longest diameter among all nodules was 4-5 mm 
𝑑2    = longest diameter among all nodules was 6-7 mm 
𝑑3    = longest diameter among all nodules was 8-10 mm 
𝑑4    = longest diameter among all nodules was 11-13 mm 
𝑑5    = longest diameter among all nodules was 14 mm or larger 
𝑝    = at least one nodule with spiculated margins was present 
𝑚    = at least one nodule with smooth margins was present 
𝑢    = at least one nodule was present in the upper lobes 
𝑔    = if evaluable, an existing nodule grew during the most recent screening interval 
Approach for Selecting Detailed CT Features for Inclusion in Models 
We considered detailed CT features that might relate to future lung cancer risk in 3 separate 
settings: interval cancers among recent screen-negatives, screen-detected cancers among recent 
screen-negatives, and screen-detected cancers among recent false-positives. In each instance, we 
considered a set of relevant variables that we created to reflect the overall features observed on a CT 
screen (Table 4.1). Each variable was modeled as an interaction with the logit of pre-screening risk. 
Using the set of relevant variables, we applied two approaches for variable selection in each case:  
a) Backwards-stepwise selection: We performed backwards-stepwise selection using the “step” 
function in R. This technique begins with the inclusion of all variables and then removes them 
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one-by-one to find the model with the minimum value of the Akaike Information Criterion 
(AIC).  
b) Lasso: The lasso (least absolute shrinkage and selection operator) is a penalized variable 
selection technique that “shrinks” coefficient values toward zero depending on the value of a 
penalization parameter, thus selecting only a subset of variables for inclusion in a regression 
model.139 For the penalization parameter, we averaged between the value that a) gave the 
minimum cross-validated error and b) was the largest value such that the cross-validated error 
was within 1 standard error of the minimum error. Although ad hoc, we found that this was the 
best approach to yield a reasonable number of selected variables. 
Given that we considered many potential variables, we took a cautious approach for 
including variables in final models. Among the variables selected by at least one approach, we 
selected variables for final models by excluding those that a) were not strongly statistically significant, 
b) lacked strong biological plausibility or interpretability, c) appeared to be driven by a small number 
of cases within a small group, or d) were better captured by other features also included in the model. 
The variables selected by each technique, along with the variables included in final models, are shown 
below in Table 4.2. A description of each variable is given in Table 4.1. 
 
4.7  Supplementary Results 
Consistency of Exponents across Intervals and Screens 
 In initial analyses, we separately evaluated risk at each NLST screen (T1, T2) and during each 
interval (T0-T1, T1-T2, 1 year following T2). For interval cancers, estimating exponents separately by 
interval gave risk calculations of {r0(x)}1.29 for the T0-T1 interval, {r0(x)}1.40 for the T1-T2 interval, 
and {r0(x)}1.31 for the 1-year interval following T2. Based on a likelihood ratio test (2 df), there was 
not statistically significant heterogeneity among these exponents (p=0.32). 
 For screen-detected cancers, among screen-negatives, estimating exponents separately by 
screen gave risk calculations of {r0(x)}1.03 for risk at the T1 screen and {r0(x)}0.99 for risk at the T2 
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screen. Among false-positives, estimating exponents separately by screen gave {r0(x)}0.76 at the T1 
screen and {r0(x)}0.72 at the T2 screen. A likelihood ratio test (2 df) indicated that these exponents did 
not vary significantly across screens (p=0.07). 
Effect of Prior Screen Results Once a More Recent Result is Known 
Our first-order Markov transition model assumes that future risk depends on the most 
recent screen result, but not on results occurring before that. To test this assumption, we compared 
individuals with the same result for the most recent screen, but a different result for the prior screen; 
risk calculations would differ between these groups if they are influenced by the prior result. 
For interval cancers, the most recent screen result is negative by definition. In one combined 
model, we examined risks for a) interval cancer during the T1-T2 interval, comparing those who 
screened negative at both T0 and T1 to those who screened false-positive at T0 but negative at T1; 
and b) interval cancer during the one-year period following T2, comparing those who screened 
negative at both T1 and T2 to those who screened false-positive at T1 but negative at T2. For the 
negative/negative group, the risk calculation was {r0(x)}1.35, compared to {r0(x)}1.33 for the false-
positive/negative group. These exponents were not statistically significantly different (p=0.97). 
For screen-detected cancers, we compared risks for screen-detected cancer at T2 (since at 
the T2 screen, two past screen results are known). We first compared risk of screen-detected cancer 
at T2 between those who screened negative at both T1 and T0 and those who screened negative at 
T1 but false-positive at T0. For the T0-negative/T1-negative group, the risk calculation at T2 was 
{r0(x)}1.00, compared to {r0(x)}0.92 for the T0-false-positive/T1-negative group. These exponents were 
not statistically significantly different (p=0.23), though we note that the point estimates for the 
exponents do suggest that there may be some small reassurance provided by sequential negative CTs. 
Next, we compared risk of screen-detected cancer at T2 between those who screened false-
positive at both T1 and T0 to those who screened false-positive at T1 but negative at T0. For the T0-
false-positive/T1-false-positive group, the risk calculation at T2 was {r0(x)}0.72, compared to 
{r0(x)}0.70 for the T0-negative/T1-false-positive group. These exponents were not statistically 
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significantly different (p=0.63). A likelihood ratio test (2 df) for the overall hypothesis that prior 
screen results do not contribute to risk calculations (i.e., regardless of most recent screen result) for 
screen-detected cancer was also not significant (p=0.47). The result for screen-detected cancer is 
shown graphically in Figure 4.1. 
Model Estimation using GEE 
Most individuals contributed multiple observations to each model (i.e., one observation per 
screen or interval), although they could only be a case once. To ensure our results were not impacted 
by correlation between screen results within the same individual, we re-estimated our final log-
binomial models using generalized estimating equations (GEE) as a sensitivity analysis. The impact 
on the variance of our estimates was negligible (data not shown).  
Estimation of Screen-detected Cancer Risk using Lung-RADS 
Exponents based on Lung-RADS categories to calculate screen-detected lung cancer risk 
following a false-positive CT screen are shown in Table 4.6. As expected, the model assigned higher 
future risk of screen-detected cancer to higher Lung-RADS categories; e.g., the exponent for pre-
screening risk for category 4B was 0.51 compared to 0.84 for category 2 (smaller exponents imply 
increased risk). Based on a comparison of the AIC, our false-positive model based directly on CT-
image features (Figure 4.5) performed better than the model based on Lung-RADS categorization 
(AIC 1903 vs. 1978, Table 4.6) and also substantially better than a model including Lung-RADS 
categories alone and excluding pre-screening risk (AIC 2023, model not shown). 
CT Features and Risk of Interval Cancers 
We defined an “interval cancer” as a cancer arising within 12 months of a negative screen 
and before the subsequent screen occurred. As we did for screen-detected cancers, we investigated 
the association between specific features noted on a (negative) CT and the subsequent risk of 
diagnosis with an interval cancer. We found that risk of an interval cancer was very low, but was 
notably higher among those whose CT noted either adenopathy or consolidation (Figure 4.4). 
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To better understand this observation, we investigated the recommended follow-up for 
these cases. Among 43 total interval cancers, 9 had either adenopathy or consolidation noted on the 
negative CT preceding their diagnosis. Among these 9, 4 were recommended to follow up after their 
“negative” CT with a diagnostic CT (N=2), biopsy (N=1), or repeat CT in 3 months (N=1). Among 
the overall group of participants with a negative CT that noted adenopathy or consolidation, a much 
larger proportion were recommended to follow up sooner than 12 months (23%) compared to those 
without such features on CT (2%).  
Thus, we concluded that although these features confer increased risk of lung cancer diagnosis, 
they do not appropriately represent features associated with risk of an interval cancer following a 
negative CT. Rather, CTs noting adenopathy or consolidation should arguably be defined as positive 
screens and followed up as such. Indeed, a retrospective review of the negative CTs that immediately 
preceded NLST interval cancers found that 91% of such CTs, upon re-review, met the NLST criteria 
for a positive screen.137 
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4.8  Tables and Figures 
 
Table 4.1 List and description of all variables that describe specific features identified on CT 
Variable 
Description: Except where indicated, all variables were binary and indicated the 
presence or absence of the factor described. 
Adenopathy Any non-calcified hilar/mediastinal adenopathy or mass (≥10 mm on short axis) 
Any nodule At least one non-calcified nodule or mass with a diameter ≥4 mm  
Atelectasis Atelectasis, segmental or greater 
Benign nodule Any benign lung nodule(s) 
Consolidation Consolidation 
Emphysema Emphysema 
Ground glass attenuation Any non-calcified nodule or mass with diameter ≥4 mm whose predominant attenuation is 
ground glass 
Growth during previous 
interval 
Any non-calcified nodule or mass with diameter ≥4 mm that had interval growth based on 
comparison with prior CT 
Lingular location Any non-calcified nodule or mass with diameter ≥4 mm whose epicenter is in the lingula 
Longest nodule diameter Continuous*: longest diameter in millimeters among all non-calcified nodules or masses 
with diameter ≥4 mm 
Lower lobe(s)  Any non-calcified nodule or mass with diameter ≥4 mm whose epicenter is in the right or 
left lower lobe 
Micronodule Any non-calcified micronodule(s) (opacity <4 mm) 
Mixed attenuation Any non-calcified nodule or mass with diameter ≥4 mm whose predominant attenuation is 
mixed 
Multi-nodules Six or more nodules not suspicious for cancer (opacity ≥4 mm) 
Number of nodules Continuous: number of nodules as described in “any nodule” 
Opacities, fibrosis, scarring Any reticular/reticulonodular opacities, honeycombing, fibrosis, or scar 
Other abnormality (high) Other potentially significant abnormality above the diaphragm 
Other abnormality (low) Other potentially significant abnormality below the diaphragm 
Other attenuation Any non-calcified nodule or mass with diameter ≥4 mm whose predominant attenuation is 
other than those described above 
Pleural thickening or effusion Pleural thickening or effusion 
Poorly defined margins Any non-calcified nodule or mass with diameter ≥4 mm whose margins are poorly defined 
Right middle lobe  Any non-calcified nodule or mass with diameter ≥4 mm whose epicenter is in the right 
middle lobe 
Smooth margins Any non-calcified nodule or mass with diameter ≥4 mm whose margins are smooth 
Soft tissue attenuation Any non-calcified nodule or mass with diameter ≥4 mm whose predominant attenuation is 
soft tissue 
Spiculated margins Any non-calcified nodule or mass with diameter ≥4 mm whose margins are spiculated 
(stellate) 
Suspicious change in 
attenuation 
Any non-calcified nodule or mass with diameter ≥4 mm that had an interval suspicious 
change in attenuation based on comparison with prior CT 
Unclassifiable attenuation Any non-calcified nodule or mass with diameter ≥4 mm whose predominant attenuation 
cannot be determined 
Unclassifiable margins Any non-calcified nodule or mass with diameter ≥4 mm whose margin type cannot be 
determined 
Upper lobe(s)  Any non-calcified nodule or mass with diameter ≥4 mm whose epicenter is in the right or 
left upper lobe 
 
*Subsequently categorized; see footnote for Table 4.2. 
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Table 4.2 Selection of variables describing features identified on CT for inclusion in models of interval cancers, 
screen-detected cancer among screen-negatives, and screen-detected cancer among false-positives 
Interval cancer among screen-
negativesa 
Screen-detected cancer among 
screen-negativesb 
Screen-detected cancer among false-
positivesc 
• Adenopathy SW,L,F 
• Atelectasis 
• Benign nodule SW 




• Opacities, fibrosis, scarring 
• Other abnormality (high) SW 
• Other abnormality (low) 
• Pleural thickening or effusion 
• Adenopathy 
• Atelectasis 
• Benign nodule 
• Consolidation SW, F 
• Emphysema SW, F 
• Micronodule 
• Multi-nodules SW 
• Opacities, fibrosis, scarring SW 
• Other abnormality (high) 
• Other abnormality (low) 
• Pleural thickening or effusion 
• Adenopathy 
• Any nodule SW, F* 
• Atelectasis 
• Benign nodule 
• Consolidation 
• Emphysema SW 
• Ground glass attenuation 
• Growth during previous interval SW, L, F 
• Lingula 
• Longest nodule diameter SW, L, F** 
• Lower lobe(s) 
• Micronodule 
• Mixed attenuation SW, L 
• Multi-nodules 
• Number of nodules 
• Opacities, fibrosis, scarring 
• Other abnormality (high) 
• Other abnormality (low) 
• Other attenuation SW, L 
• Pleural thickening or effusion 
• Poorly defined margins SW 
• Right middle lobe SW 
• Smooth margins L, F 
• Soft tissue attenuation 
• Spiculated margins SW, L, F 
• Suspicious change in attenuation 
• Unclassifiable attenuation SW 
• Unclassifiable margins SW 
• Upper lobe(s) SW, L, F 
 
SW Selected by backwards stepwise approach 
L Selected by lasso  
F Selected for inclusion in final model 
a Final model shown in Figure 4.4 
b Final model shown in Figure 4.3 
c Final model shown in Figure 4.5 
*In the final model, this effect is essentially included in the diameter variable. 
**Diameter was modeled continuously during variable selection. For the final model described in Figure 3, we considered 
different parameterizations including continuous, categorical, and log, square-root, and square transformations. We chose 
the categorical approach because it gave the lowest AIC. 
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Table 4.3 Individuals and screens from the National Lung Screening Trial included in analysis of risk for interval 
and screen-detected lung cancer 
 
At risk for interval cancer At risk for screen-detected cancer 
Screen-negative Screen-negative False-positive 
Total number individuals, N 23,331 19,752 8,300 
Screens per person, N (%)    
    1 screen 4,445 (19%) 3,970 (20%) 3,606 (43%) 
    2 screens 4,176 (18%) 15,782 (80%) 4,694 (57%) 
    3 screens 14,710 (63%) -- -- 
Total number screens, N 56,927 35,534 12,994 
NLST screening round, N (%)    
    T0 19,076 (34%) 18,247 (51%) 6,484 (50%) 
    T1 17,804 (31%) 17,287 (49%) 6,510 (50%) 
    T2 20,047 (35%) -- -- 
1-year pre-screening risk, median 
(IQR) 
0.31% (0.19-0.51%) 0.31% (0.19-0.50%) 0.35% (0.21-0.58%) 
Lung cancer detected, N (%) 43 (0.076%) 138 (0.39%) 235 (1.8%) 
Lung-RADS category, N (%)    
    1 39,593 (70%) 26,512 (75%) 4 (0%) 
    2 16,867 (30%) 8.991 (25%) 8,661 (67%) 
    3  12 (0%) 5 (0%) 1,844 (14%) 
    4A 26 (0%) 18 (0%) 1,329 (10%) 
    4B 10 (0%) 6 (0%) 542 (4%) 
    4X 0 (0%) 0 (0%) 239 (2%) 
    Indeterminate or missing 418 (1%) 2 (0%) 375 (3%) 
 
We analyzed 25,762 unique individuals. Percentages may not sum exactly to 100 due to rounding. See Methods for detailed 
definitions of interval and screen-detected cancer and a description of who was considered at risk for each. Lung-RADS 
categories were assigned retrospectively as described in Pinsky et al., Ann Intern Med 2015.141 
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Table 4.4 Cross-validation for models of next-screen lung cancer detection and interval lung cancer risk that 
incorporate specific CT-image featuresa 
Predicted 
risk quintile 
Next-screen cancer among 
screen-negatives, Nb 
Next-screen cancer 
among false-positives, Nc  
Interval cancer among 
screen-negatives, Nd  
Predicted Observed Predicted Observed Predicted Observed 
Lowest 5.8 3 6.5 7 1.2 2 
Low 11.1 19 13.9 13 2.5 2 
Moderate 17.9 13 24.3 31 4.3 8 
High 29.9 33 45.3 43 7.6 8 
Highest 73.7 70 147.9 141 29.1 23 
Total 138.4 138 238.0 235 44.8 43 
 
a Ten-fold cross-validation was performed: each model was fit 10 times using 90% of the data to generate predicted risks for 
the other 10% of the data. Data for all NLST screens (T1 and T2) and intervals (T0-T1, T1-T2, 1-year post-T2) was used. 
For each model, the model-predicted number of lung cancers is compared to the observed number of lung cancers within 
each quintile of risk. 
b Model for next-screen cancer among screen-negatives includes CT-detected emphysema and consolidation. Ten-fold 
cross-validation estimate of prediction error was 0.39% 
c Model for next-screen cancer among false-positives includes spiculated margins, smooth margins, nodule(s) in upper 
lobe(s), growing nodule(s), and longest nodule diameter. Ten-fold cross-validation estimate of prediction error was 1.72%. 
d Model for interval cancer among screen-negatives includes a binary indicator of whether adenopathy or consolidation (or 
both) were diagnosed on the CT image. Ten-fold cross-validation estimate of prediction error was 0.08%. 
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Table 4.5 Calculation of next-screen lung cancer risk following a false-positive screen, based on Lung-RADS 
categories 
Risk at next screen = r0(x)y with exponent y given as follows:  
Characteristic Exponent, y (95% CI) Prevalence 
Lung-RADS category at screen   
     2 0.84 (0.80-0.88) 69% 
     3 0.81 (0.73-0.89) 15% 
     4A 0.60 (0.55-0.65) 10% 
     4B 0.51 (0.45-0.57) 4% 
     4X 0.76 (0.60-0.98) 2% 
 
Model was fit among 12,615 individuals with a false-positive result at T0 or T1 and evaluates risk of cancer detection at T1 
or T2, respectively. We restricted to individuals in whom a Lung-RADS category could be conclusively retrospectively 
assigned, as described in Pinsky et al., Ann Intern Med 2015.141 The Akaike Information Criterion (AIC) for this model was 
1978, as compared to 1903 for our false-positive model (Figure 4.5) fit among the same individuals. 
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Table 4.6 Effect of features noted on a false-positive CT screen on 1-year risk of screen-detected lung cancer 
among participants in the National Lung Screening Trial 





Pre-screening risk (100%) 0.34% 0.21-0.57% Ref Ref 
Risk at next screen by:      
All T1 false-positives (100%) 0.91% 0.45-2.0% +0.56% 2.6 
All low-risk factors** 18.9% 0.32% 0.20-0.53% -0.02% 0.94 
Spiculated margins      
    No 90.4% 0.79% 0.42-1.7% +0.45% 2.3 
    Yes 9.6% 4.0% 2.0-7.4% +3.7% 11.7 
Smooth margins      
    No 26.8% 1.9% 0.90-3.9% +1.6% 5.5 
    Yes 73.2% 0.71% 0.37-1.5% +0.36% 2.1 
Nodule(s) in upper lobe(s)      
    No 55.1% 0.62% 0.32-1.3% +0.28% 1.8 
    Yes 44.9% 1.4% 0.71-3.1% +1.1% 4.2 
Growing nodule(s)      
    No 94.0% 0.83% 0.43-1.7% +0.48% 2.4 
    Yes 6.0% 7.7% 3.7-15.4% +7.4% 22.4 
Longest nodule diameter      
    N/A* 1.9% 1.5% 1.1-2.2% +1.2% 4.4 
    4-5 mm 39.0% 0.49% 0.28-0.85% +0.15% 1.4 
    6-7 mm 29.8% 0.80% 0.46-1.4% +0.45% 2.3 
    8-10 mm 16.4% 1.9% 1.2-3.3% +1.6% 5.5 
    11-13 mm 5.7% 4.1% 2.5-7.5% +3.8% 11.9 
    14+ mm 7.2% 4.0% 2.2-7.6% +3.6% 11.5 
 
These data describe individuals who screened positive at the second NLST screen (T1) but in whom lung cancer was not 
immediately detected, and were subsequently at risk for lung cancer at the third screen (T2) (N=6,510). The second and 
third screens were selected to allow for evaluation of nodule growth between the first and second screens, and thus 
presentation of its relation to risk at the third screen. Outliers are included in the calculations. We note that the median risk 
among all T1 false-positives (0.91%) differs from that in Figure 4.2 (1.5%) because the distribution of risks becomes much 
wider after accounting for specific CT features. The means of the two risk distributions are similar. 
*Screen was positive for a reason other than a nodule ≥4 mm 
**Defined as follows: largest nodule diameter = 4-5 mm, at least one nodule with smooth margins, and no nodules in upper 
lobe(s), with spiculation, or growth. The exponent for such an individual’s pre-screening risk would be 0.99 (95% CI 0.92-
1.06); in other words, the calculation for next-screen risk is very similar to that for a negative screen. 
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Table 4.7 Observed lung cancer incidence over 4 years following the final (T2) NLST screen, by quintile of 




Range (median) of 1-year 
predicted risks 
Observed 4-year lung 
cancer incidence 
Lowest 4,777 0.03% to 0.15% (0.11%) 0.08% 
Low 4,776 0.15% to 0.27% (0.21%) 0.48% 
Moderate 4,776 0.27% to 0.46% (0.35%) 0.77% 
High 4,776 0.46% to 0.90% (0.62%) 2.0% 
Highest 4,776 0.90% to 41% (1.6%) 3.1% 
 
Analysis included 23,881 individuals who had a negative or false-positive T2 CT screen result and no prior lung cancer 
diagnosis. Following the T2 screen, 98% of participants had at least 4 years of follow-up for lung cancer incidence. One-
year total predicted risk was calculated using our models for interval-cancer risk among screen-negatives (Figure 4.4), next-
screen cancer risk among screen-negatives (Figure 4.3), and next-screen cancer risk among false-positives (Figure 4.5). For 
screen-negatives, interval and next-screen cancer risks were summed. 
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Figure 4.1 Comparison of T2 screen-detected lung cancer risk between groups with the same screen result at T1, 






This analysis evaluated our first-order Markov assumption, in other words, evaluated whether prior screen-results continue 
to influence risk calculations once a more recent screen result is known. Exponents for risk calculation at T2 did not 
statistically significantly differ between groups whose T1 screen was negative but whose T0 screen differed (p=0.23) or 
between groups whose T1 screen was false-positive but whose T0 screen differed (p=0.63). A global likelihood ratio test (2 
df) also indicated that prior screen results (regardless of whether the most recent result was negative or false-positive) do 
not contribute to risk calculations (p=0.47). 
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Figure 4.2 Overall effect of a negative or false-positive CT screening result on 1-year risk of an interval or screen-
detected lung cancer among participants in the National Lung Screening Trial 
 
 
For illustration, this figure was constructed using data from individuals who underwent the first (T0) NLST screen and were 
at risk for lung cancer during the subsequent interval (i.e., screened negative, N=19,076) or at the subsequent (T1) screen 
(i.e., screened negative or false-positive and had a valid T1 screen result, N=24,731). Individuals for whom lung cancer was 
detected at T0 (N=270) were excluded. After this exclusion, 26% of individuals had a false-positive CT and the other 74% 
had a negative CT. Pre-screening risk r0(x) was calculated using the Lung Cancer Risk Assessment Tool.73 Outliers are not 
included in the figure, but are included in the calculations in the table. Within each group of boxplots, boxplot widths are 
scaled by the percentage of the population represented, and vertical lines in boxplots represent the range of data excluding 
outliers. IQR, interquartile range. 
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Figure 4.3 Effect of features noted on a negative CT screen on 1-year risk of screen-detected lung cancer among 
participants in the National Lung Screening Trial 
 
 
For illustration, this figure was constructed using data from individuals who screened negative at the first NLST screen (T0) 
and were subsequently at risk for lung cancer at the second screen (T1) (N=18,247). Among these individuals, 0.6% had 
consolidation identified on their negative CT, 30% had emphysema, and 70% had neither. A small number of individuals 
with both consolidation and emphysema noted at T0 were included in both corresponding risk distributions. Pre-screening 
risk r0(x) was calculated using the Lung Cancer Risk Assessment Tool.73 Outliers are not included in the figure, but are 
included in the calculations in the table. Within each group of boxplots, boxplot widths are scaled by the percentage of the 
population represented, and vertical lines in boxplots represent the range of data excluding outliers. IQR, interquartile 
range. 
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Figure 4.4 Effect of features noted on a negative CT screen on 1-year risk of interval lung cancer among 




For illustration, this figure was constructed using data from individuals who screened negative at the first NLST screen and 
were subsequently at risk for lung cancer during the interval between the first and second screens (N=19,076). Pre-
screening risk (r) was calculated using the Lung Cancer Risk Assessment Tool.73 Outliers are not included in the figure, but 
are included in the calculations in the table. Within each group of boxplots, boxplot widths are scaled by the percentage of 





(before negative CT) 




Risk calculation r0(x) r0(x)
1.37 r0(x)
0.89 
Exponent 95% CI NA (1.30, 1.43) (0.77, 1.02) 
Median 0.31% 0.04% 0.66% 
IQR 0.19-0.51% 0.02-0.07% 0.44-1.1% 
Median difference Ref -0.27% +0.35% 
Median ratio Ref 0.12 2.1 
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Figure 4.5 Effect of features noted on a false-positive CT screen on 1-year risk of screen-detected lung cancer 
among participants in the National Lung Screening Trial 
 
 
*Screen was positive for a reason other than a nodule ≥4 mm 
For illustration, this figure was constructed using data from individuals who screened positive at the second NLST screen 
(T1) but in whom lung cancer was not immediately detected, and were subsequently at risk for lung cancer detection at the 
third screen (T2) (N=6,510). The second and third screens were selected to allow for evaluation of nodule growth between 
the first and second screens, and thus presentation of its relation to risk at the third screen. Pre-screening risk r0(x) was 
calculated using the Lung Cancer Risk Assessment Tool.73 Outliers are not included in the figure, but are included in the 
calculations in the table. Within each group of boxplots, boxplot widths are scaled by the percentage of the population 
represented, and vertical lines in boxplots represent the range of data excluding outliers. IQR, interquartile range. 
  
Risk at next screen after a false-positive screen = r0(x)
y with exponent y calculated as follows:  
Characteristic	 Value (95% CI)	
What was the longest diameter among all nodules?	 This gives the initial value	
     N/A*	 0.76 (0.62-0.95)	
     4-5 mm	 0.92 (0.84-1.00)	
     6-7 mm	 0.85 (0.78-0.93)	
     8-10 mm	 0.73 (0.66-0.80) 	
     11-13 mm	 0.63 (0.56-0.71)	
     14 mm or larger	 0.68 (0.62-0.76)	
Was any nodule with spiculated margins present?  	 If yes, subtract 0.10 (-0.15, -0.04)	
Was any nodule with smooth margins present?	 If yes, add 0.07 (0.02, 0.12)	
Was any nodule present in the upper lobes?	 If yes, subtract 0.10 (-0.15, -0.04)	
If evaluable, did an existing nodule grow during the most recent 
screening interval? 	
If yes, subtract 0.28 (-0.34, -0.22)	
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Chapter 5: Conclusions 
5.1  Summary of Results 
This dissertation applied precision approaches for cancer screening in two high-risk 
populations (PLHIV and heavy smokers), and for three types of cancer (cervical, anal, and lung 
cancers). While each context was unique, the ultimate goal of this work is the same in each case: to 
identify ways that cancer screening can be tailored to each individual, thus achieving a better overall 
balance of benefits and harms at the population level. 
Chapter 2 used a risk benchmarking framework to compare cervical precancer risks between 
U.S. WLHIV (in the Women’s Interagency HIV Study) and general population women. This 
framework allowed explicit suggestion of particular screening or management strategies following 
different cytology and/or oncHPV testing results. We found that most existing CDC guidelines for 
WLHIV were supported by this risk comparison, including: a 3-year return after 3 consecutive 
negative cytologies or a negative cytology/oncHPV co-test for WLHIV with CD4≥500; a 1-year 
return after negative cytology with either a positive oncHPV co-test or a CD4<500; and a 6-12 
month return after ASC-US cytology for CD4≥350. Other findings differed from current guidelines, 
including: colposcopy instead of a 6-12 month return for WLHIV with ASC-US and CD4<350; and 
a 2-year instead of 1-year interval for WLHIV with CD4≥500 after negative cytology. In sum, our 
findings largely supported current guidelines for cervical cancer screening in WLHIV, but also 
suggested that CD4 cell count might be considered in some instances to permit more tailored 
screening strategies. 
Chapter 3 analyzed data from the Multicenter AIDS Cohort Study to describe patterns of 
repeated anal cytology among HIV-positive and HIV-negative MSM. We found that among men 
with an initial negative cytology, the second cytology was most likely to remain negative among HIV-
negative men (83%) and less likely to remain negative among HIV-positive men with CD4≥500 
(74%) or CD4<500 (68%). Similarly, after an initial abnormal cytology, the second cytology was least 
likely to remain abnormal among HIV-negative men (46%) or HIV-positive men with CD4≥500 
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(53%), and most likely to remain abnormal among HIV-positive men with CD4<500 (70%). Among 
HIV-positive MSM, about 37% have consistently negative cytology over 3 years, which may identify 
a low-risk group in whom an invasive procedure such as HRA is unlikely to be beneficial. HIV-
positive men with consistently negative cytology, as compared to those with consistently abnormal 
cytology, were likely to have higher current and nadir CD4 counts and fewer recent condomless 
receptive anal sex partners, consistent with known risk factors for anal lesions and cancer. 
Finally, Chapter 4 analyzed data from the National Lung Screening Trial to develop a risk 
model that continually updates individual lung cancer risk during CT screening. We found that those 
with a false-positive CT have overall increased lung cancer detection at the next annual screen, while 
screen-negatives have detection similar to their one-year risk prior to screening. However, there is 
heterogeneity in each of these groups. Screen-negatives with CT-detected emphysema or 
consolidation have increased risk when they return for the next screen, while the 70% without either 
of these features have 1.8-fold reduced next-screen detection. This 70% of screen-negatives, who 
comprised 51% of National Lung Screening Trial participants, represents a logical first group to 
consider for longer screening intervals. Next-screen detection among false-positives varies widely by 
nodule features, but for false-positives with all low-risk features (19%), future risk is equivalent to 
that following a negative screen. 
 
5.2  Opportunities for Future Research 
Each of the three contexts studied within this dissertation has unique opportunities for future 
research, and there are additional research avenues that are relevant across all three aims. To optimize 
cervical cancer screening in WLHIV, there are a few scenarios that we could not address but that 
should be studied in future work. These include risk-based screening strategies following primary 
(standalone) HPV testing, the utility of type-specific HPV testing for risk stratification including in 
conjunction with CD4 count, risk-tailored screening strategies appropriate for WLHIV in low-
resource settings, the utility of HIV viral load measurements for risk stratification, whether full 
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immunosuppression (CD4 count) history must be considered for screening decisions, and whether 
broad screening recommendations are appropriate for special groups of WLHIV such as those with a 
history of cervical precancer treatment. 
Anal cancer screening among MSM is a context with a substantial and wide-ranging need for 
additional research, and multiple specific questions follow directly from our results. In particular, 
patterns of anal cytology (e.g., consistently negative cytology over 3 years) should be studied in their 
relation to the risk of biopsy-confirmed HSIL: here we would expect that consistently negative 
cytology might indicate sufficiently low risk to safely avoid referral to HRA. We examined the effect 
of current CD4 cell count on the likelihood of transitioning from one cytology result to another (e.g., 
from normal to abnormal), but it is possible that other factors such as nadir CD4 cell count, HIV 
viral load, or demographic factors such as age also play an important role. Finally, since there are 
major demographic differences between our study population (MACS participants) and the current 
population of HIV-positive MSM in the U.S., it would be of interest to examine statistically whether 
our pap-pattern prevalence estimates are likely to represent HIV-positive MSM more broadly. 
Similarly, CT lung cancer screening is a new field with a multitude of research needs. 
Following from our findings, perhaps most importantly, it will be critical to externally validate our 
risk model in an appropriate population before it can be applied in practice. Our finding that only the 
most recent CT result contributed to risk calculations is novel and important, but should be re-
examined using data describing more than 3 annual CT screens. We identified a subset of CT 
participants – namely, those with a negative CT result and no emphysema or consolidation – who are 
likely candidates for extended screening intervals, and additional research is needed to identify precise 
appropriate risk thresholds for longer intervals and to examine the impact of such a strategy on CT 
screening programs overall. Similarly, at the other end of the risk spectrum, our findings identify a 
small subset of false-positives who have very high predicted probabilities of next-screen lung cancer 
detection. Future studies should seek to describe these participants and to examine potential 
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strategies for appropriate follow-up testing that may occur sooner than the recommended next 
annual screen. 
 Finally, there are avenues of future work that are applicable to precision cancer screening in 
general and thus common to all three dissertation aims. Precision cancer screening strategies, by their 
nature, require individualized assessment of patients’ cancer risks and the application of screening 
strategies that are complex and differ across patients. Research is needed to understand the 
implications of such strategies for clinical workflows, to identify approaches that automate and 
streamline processes for clinicians, and to develop tools that allow clinicians to effectively and 
efficiently communicate with patients in a way that improves shared decision-making. Success in 
implementation will require interdisciplinary research efforts that engage clinicians, patients, and 
researchers from a variety of fields. 
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  Advisor: Dr. Gypsyamber D’Souza 
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Sep. – Dec. 2016 Site Coordinator 
 Oral HPV Infection and Persistence in HIV (OHIP) Study 
 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
  
Oct. 2012 – Aug. 2014 Post-Baccalaureate Fellow 
 Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD 
 Mentors: Dr. Eric Engels and Dr. Mahboobeh Safaeian 
  
May – Sep. 2012 Epi Scholar 
 Los Angeles County Department of Public Health, Los Angeles, CA 
  
Jan. – Apr. 2012 Research Assistant 
 Center for American Indian Health, Johns Hopkins, Baltimore, MD 
  
Jan. – June 2011 Community Health Volunteer Researcher 
 ATRAVES, Managua, Nicaragua 
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 Colegio Bilingüe New Horizons, Santo Domingo, Dominican Republic 
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 Dr. Eric Toone's chemistry laboratory, Duke University, Durham, NC 
 Dr. Blanche Capel's biology laboratory, Duke University, Durham, NC 
 Dr. Thomas Schmedake's biochemistry laboratory, UNCC, Charlotte, NC 
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Awarded to a biostatistics master’s student for the best performance on the first-year written 
comprehensive examination. Department of Biostatistics, Johns Hopkins Bloomberg School of 
Public Health, Baltimore, MD 
  
June 2017 ICSN Conference Travel Award 
 International Cancer Screening Nework Meeting, Bethesda, MD 
  
May 2017 1st Place Poster, Clinical and Translational Research 
 
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC) Fellow Research Day 
2017, Baltimore, MD 
  
May 2017 ATS Abstract Travel Scholarship 
 American Thoracic Society (ATS) 2017 Conference, Washington, DC 
  
May 2017 ATS Student Scholars Program 
 American Thoracic Society (ATS) 2017 Conference, Washington, DC 
  
April 2017 David and Elinor Bodian Scholarship 
 
Awarded to a doctoral student whose dissertation research is at a critical juncture. Johns 
Hopkins Bloomberg School of Public Health, Baltimore, MD 
  
Mar. 2017 Alison Snow Jones Prize in Health Policy & Management 
 
Awarded to a doctoral student for excellence in a thesis research manuscript. Johns Hopkins 
Bloomberg School of Public Health, Baltimore, MD 
  
Mar. 2017 3rd Place Poster, Applied Research 
 
Delta Omega Poster Competition, Johns Hopkins Bloomberg School of Public Health, 
Baltimore, MD 
  
Feb. 2017 International Papillomavirus Society Travel Award 
 HPV 2017: 31st International Papillomavirus Conference, Cape Town, South Africa 
  
Nov. 2016 Scholar-in-Training Travel Award 
 
AACR Special Conference on Improving Cancer Risk Prediction for Prevention and Early 
Detection, Orlando, FL 
  
May 2016 Honorable Mention Poster, Clinical and Translational Research 
 
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC) Fellow Research Day 
2016, Baltimore, MD 
  
Apr. 2016 Carol Eliasberg Martin Scholarship 
 
Awarded to a doctoral student or post-doc whose research holds promise for preventing 
cancers that affect women. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
  
Feb. 2016 Women in Cancer Research (WICR) Scholar Travel Award 
 AACR 2016 Annual Meeting, New Orleans, LA 
  
Oct. 2015 Translating Cancer Epidemiology Conference Travel Award 
 
Translating Cancer Epidemiology: From Cells to Clinic and Population, Huntsman Cancer 
Institute, Salt Lake City, UT 
  
Mar. 2015 Jean Coombs Award 
 
Awarded to a doctoral student whose dissertation concerns cancer or childhood diseases. Johns 
Hopkins Bloomberg School of Public Health, Baltimore, MD 
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Aug. 2014 Cancer Epidemiology, Prevention, and Control Training Grant 
 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
  
Dec. 2013 CROI Young Investigator Travel Award 
 Conference on Retroviruses and Opportunistic Infections (CROI) 2014 
  
Nov. 2013 DCEG Fellows Award for Research Excellence 
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contributions to research projects. Division of Cancer Epidemiology and Genetics, NCI, NIH, 
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of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD 
  
May 2013 Outstanding Poster Award 
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Apr. 2013 Delta Omega Honor Society 
 
Members are inducted through a selective process that assesses their outstanding performance 
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 Center for Global Health, Johns Hopkins University, Baltimore, MD 
  
Dec. 2011 Sara’s Wish Foundation Scholarship 
 
Awarded to young women who exhibit qualities of leadership, service, and adventure to 
support travel for international humanitarian work. Sara’s Wish Foundation, Amherst, MA 
  
May 2010 Magna Cum Laude 
 Duke University, Durham, NC 
  
Dec. 2009 Phi Beta Kappa 
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 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
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 Duke University, Durham, NC 
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 Duke University, Durham, NC 
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 Johns Hopkins University, Baltimore, MD 
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“Optimizing Screening for HPV-Related Cancers Among People Living with HIV” 
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women and for anal cancer among HIV-positive and -negative men who have sex with men. 




May 2016 Wrote article about skin cancer among transplant recipients for the Skin Cancer Foundation’s 
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Available at: http://www.skincancer.org/prevention/are-you-at-risk/transplants 
  
Jan. 2015 Created page of “Common questions and answers about oral HPV infection” for the Oral 
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for HPV-positive head and neck cancer. Oral Oncology 2018;77:52-56. PMID 29362127. 
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2014 Jan 13;3:328. PMC3888946. 
 
Published Commentaries, Editorials, and Letters 
 
1. Robbins HA. CT lung cancer screening in people living with HIV: Modeling to bridge the evidence. 
Invited commentary on “Benefits and harms of lung cancer screening in HIV-infected individuals 
with CD4+≥500: A simulation study” by Kong et al. AIDS, in press. 
  
2. D’Souza G and Robbins HA. Sexual and relationship health among survivors of oropharyngeal or 
oral cavity squamous cell carcinoma. Invited commentary on “Significant changes in sexual behavior 
after a diagnosis of HPV-positive and negative oral cancer” by Taberna et al. Cancer 2017 Apr 
1;123(7):1092-109. PMC5538106. 
 
3. Marcus PM, Pashayan N, Church TR, Doria-Rose VP, Gould MK, Hubbard RA, Marrone M, 
Migliorettie DL, Pharoah PD, Pinsky PF, Rendle K, Robbins HA, Roberts MC, Rolland B, 
Schiffman M, Tiro JA, Zauber AG, Winn DM, Freedman AN, Khoury MJ. Population-based 
precision cancer screening: a symposium on evidence, epidemiology, and next steps. Cancer Epidemiol 
Biomark Prev 2016 25(11):1449–55. PMC5165650. 
 
4. Shiels MS, Robbins HA, Engels EA. Younger age at cancer diagnosis may be driven by age structure 
of the HCV population. J Hepatol 2016 Feb;64(2):516-7. PMC5373652. 
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Invited Oral Presentations 
 
Dec. 1, 2017 “Human Papillomavirus” 
 Lecture to Epidemiology of Infectious Diseases course 
 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 
  
July 4, 2017 “Precision Medicine for Cancer Screening: Applications in Lung and Cervical Cancers” 
 Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), 
Lyon, France 
  
Jan. 19, 2017 “Precision Medicine for Cancer Screening: Applications in Lung and Cervical Cancers” 
 Epidemiology and Clinical Outcomes Research Seminar Series 
 Washington University in St. Louis School of Medicine, St. Louis, MO 
  
July 1, 2014 “Measurement of Human Papillomavirus Immune Responses”  
 With Dr. Mahboobeh Safaeian, as a section of “Human Papillomavirus Seroepidemiology 
in Natural History and Vaccination Studies” 
 MedImmune, Gaithersburg, MD 
 
Proffered Oral Presentations 
 
June 20, 2017 
“Effect of Screening CT Results on Lung Cancer Risk Prediction within the National Lung 
Screening Trial” 
 International Cancer Screening Network (ICSN) Meeting, Bethesda, MD 
  
May 24, 2017 
“Effect of Screening CT Findings on Lung Cancer Risk Prediction Within the National 
Lung Screening Trial” 
 American Thoracic Society (ATS) 2017 International Conference, Washington, DC 
  
Mar. 4, 2017 
“Cervical Cancer Screening Intervals and Management of Abnormal Results for Women 
Living with HIV: A Risk Benchmarking Approach” 
 HPV 2017: 31st International Papillomavirus Conference, Cape Town, South Africa 
  
Nov. 18, 2016 
“Effect of Screening CT Findings on Lung Cancer Risk Prediction within the National 
Lung Screening Trial” 
 
AACR Conference on Improving Cancer Risk Prediction for Prevention and Early 
Detection, Orlando, FL 
  
Mar. 8, 2016 “Optimizing Screening for HPV-related Cancers among People Living with HIV” 
 Doctoral Proposal Seminar, JHSPH, Baltimore, MD 
  
June 18, 2014 “Measurement of HPV Immune Responses: Comparing Serology Assays” 
 Post-baccalaureate Seminar Series, NIH, Bethesda, MD 
  
Apr. 10, 2014 
“Epidemiologic Factors Contributing to Cancer Trends in the U.S. HIV-Infected 
Population” 
 Seminars by DFARE Winners, DCEG, NCI, NIH, Rockville, MD 
  
Dec. 12, 2013 “Epidemiologic Contributions to Cancer Trends Among HIV-Infected People” 
 Registry Database Studies Seminar Series, DCEG, NCI, NIH, Rockville, MD 
  
Nov. 14, 2013 “Excess Burden of Cancer among HIV-Infected Persons in the United States” 
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Nov. 13, 2013 
“Epidemiologic Contributions to Recent Cancer Trends Among HIV-Infected People in 
the United States” 
 
14th International Conference on Malignancies in AIDS and Other Acquired 
Immunodeficiencies (ICMAOI), NIH, Bethesda, MD 
  
Apr. 13, 2013 
"Correlates of Intimate Partner Violence during Pregnancy: A Multilevel Analysis of the 
Los Angeles Mommy and Baby Project" 
 
Student Leaders in Global Health, Unite for Sight Global Health and Innovation 




Apr. 5, 2017 
“Effect of Screening CT Findings on Lung Cancer Risk Prediction Within the National 
Lung Screening Trial” 
 American Association for Cancer Research (AACR) 2017, Washington, DC 
  
Apr. 18, 2016 “Optimizing Cervical Cancer Screening for HIV-infected Women: A Risk-based Approach” 
 American Association for Cancer Research (AACR) 2016, New Orleans, LA 
  
Oct. 26, 2015 
“Screening Interval after Normal Cervical Cytology among HIV-infected Women: A Risk-
based Approach” 
 
15th International Conference on Malignancies in AIDS and Other Acquired 
Immunodeficiencies (ICMAOI), NIH, Bethesda, MD 
  
Oct. 24, 2015 “Excess Cancers among HIV-infected People in the United States” 
 Translating Cancer Epidemiology: From Cells to Clinic and Population 
 Huntsman Cancer Institute, Salt Lake City, UT 
  
June 16, 2015 “Age at Cancer Diagnosis for Blacks Compared with Whites in the United States” 
 Society for Epidemiologic Research 2015 Annual Meeting, Denver, CO 
  
Aug. 24, 2014 
“Immunogenicity Assessment of HPV16/18 Vaccine using the Glutathione S-Transferase 
Multiplex Serology Assay” 
 HPV 2014: 29th International Papillomavirus Conference, Seattle, WA 
  
May 1, 2014 
“Immunogenicity Assessment of HPV16/18 Vaccine using the Glutathione S-Transferase 
Multiplex Serology Assay” 
 Post-Baccalaureate Poster Day, NIH, Bethesda, MD 
  
Mar. 5, 2014 “Excess Burden of Cancer Among HIV-Infected Persons in the United States” 
 Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA 
  
June 18, 2013 
“Epidemiologic Contributions to Changing Cancer Incidence in the U.S. HIV Population, 
1996-2008” 
 Society for Epidemiologic Research Annual Meeting, Boston, MA 
  
May 1, 2013 
“Utility of Glutathione S-Transferase Multiplex Serology as a Measure of Exposure and 
Immunity to Human Papillomavirus among Unvaccinated Women” 
 Post-Baccalaureate Poster Day, NIH, Bethesda, MD 
  
Mar. 15, 2013 
"Correlates of Intimate Partner Violence during Pregnancy: A Multilevel Analysis of the Los 
Angeles Mommy and Baby Project" 
 Consortium of Universities for Global Health Annual Meeting, Washington, DC 
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Manuscript Review 
 
AIDS (2014, 2017, 2018) 
AIDS Research and Human Retroviruses (2016) 
Annals of the American Thoracic Society (2017) 
British Journal of Dermatology (2017) 
Cancer Epidemiology (2015) 
Cancer Epidemiology, Biomarkers & Prevention (2015, 2018) 
Cancer Medicine (2017) 
Clinical and Vaccine Immunology (2015) 
Epidemiology and Infection (2016) 
Human Vaccines & Immunotherapeutics (2014, 2015) 
JAIDS (2016, 2017) 
Journal of Clinical Microbiology (2016) 
Journal of Infection (2014) 
Journal of Infectious Diseases (2016) 
PLoS One (2015) 
Preventive Medicine (2017) 
Public Health Reports (2016) 





2015 – present American Association for Cancer Research (AACR) 
2014 – present International Papillomavirus Society (IPVS) 
2012 – present Society for Epidemiologic Research (SER) 
2015 – 2017 American Statistical Association (ASA) 
2016 – 2017 American Thoracic Society (ATS) 




Software: R, Stata, SAS, SEER*Stat; Joinpoint, Endnote, Reference Manager, Mendeley, ArcGIS (basic), 
RedCap (basic), Microsoft Word, Excel, PowerPoint, and Outlook 
Languages: English (native), Spanish (full professional proficiency) 
 
 
 
